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Prostate cancer (PCa) is the most commonly diagnosed cancer in U.S. men and 
disproportionately affects black men more than any other racial or ethnic group. Despite 
this disparity, black men have been underrepresented in previous studies. PCa is 
commonly treated using androgen deprivation therapy (ADT). However, ADT induces 
numerous adverse side effects, including loss of muscle mass, strength, power, and 
physical function with concomitant increases in fat mass, fatigue, and bone fractures. 
Because strength training (ST) can reverse these factors in healthy older adults, it was 
hypothesized that ST would be effective in PCa patients on ADT but with an attenuated 
response. Therefore, the purpose of this study was 1) to examine the effects of ST on 
musculoskeletal and body composition side effects in black men on ADT, 2) to compare 
ST responses of black PCa patients on ADT to those of black healthy reference controls, 
  
and 3) to determine if changes in musculoskeletal health and body composition with ST 
are associated with changes in fatigue, physical function, and quality of life (QoL). 
PCa patients (N=17) completed a 12 week ST program, which produced many 
beneficial effects on factors adversely affected by ADT, including substantial gains in 
muscle power, size, strength, and endurance (all P < 0.001), resulting in a more favorable 
body composition (P < 0.001) and increased physical function (all P < 0.05). ST also 
improved fatigue perception and QoL (both P < 0.05). Compared with healthy reference 
controls (N=20), PCa patients responded to ST with similar gains in muscle power, 
strength, and mass, which was contrary to expectations. However, PCa patients had 
higher fat mass and lower muscle power and strength than controls at baseline (all P < 
0.05). Finally, the changes in physical function, fatigue perception, and QoL were 
associated with some of the changes in muscle function with training. The findings in this 
study provide support for the hypothesis that ST improves musculoskeletal health and 
body composition in black men with PCa on ADT by demonstrating significant 
improvements in muscle power, mass, strength, and endurance, which can enhance 
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Prostate cancer (PCa) is the most commonly diagnosed cancer in men. It is 
estimated that ~217,730 men in the U.S. will be diagnosed with PCa in 2010 alone and 
that ~32,050 will die by the end of the year (101). It is the most common type of hormone 
dependent tumor, the most commonly diagnosed non-dermatological malignancy in men, 
and the second leading cause of mortality due to cancer in the U.S. (101). While PCa 
incidence and mortality rates have improved in general, there is a large racial disparity 
that currently exists. Black men have the highest incidence of PCa than any other racial 
or ethnic group throughout the world, with 234.6 cases per 100,000 men compared with 
150.4 per 100,000 for whites (101), and die of PCa at 2.4 times the rate of white men (2). 
This death rate increases to three times the rate of whites when examining men under the 
age of 65 (1).  
Because PCa tumors have been shown to be hormone dependent (87), androgen 
deprivation therapy (ADT) is a classic form of treatment. Although this treatment is 
effective in slowing tumor growth, the suppression of endogenous testosterone reduces 
muscle strength (6, 65, 211), mass (20, 65, 186, 201), and bone mineral density (BMD) 
(33, 62, 65, 72) and increases fat mass (20, 62, 184, 201) and generalized fatigue 
perception (62, 103, 119, 190). The collective effect of ADT is a functional decline 
leading to reduced performance in activities of daily living (35, 65, 103, 125) and 
deteriorating quality of life (QoL) (6, 29, 40, 190). Although not directly assessed in 
previous cancer studies, it is quite likely that ADT increases fat infiltration in muscle, 
leading to the accumulation of intermuscular fat (IMF) and subcutaneous fat (SCF) (99). 




resistance and  type 2 diabetes (71), both co-morbidities with high prevalence in patients 
on ADT (7, 21). In addition, fat infiltration is associated with reduced strength (70), 
poorer leg function  (202, 204), and greater incidence of mobility limitations in older 
adults (203). 
 These iatrogenic effects of ADT are similar to those associated with typical aging 
(sarcopenia) (75, 91), but occur at an accelerated rate (Figure 1). Strength training (ST)  
can reverse many of the factors associated with both the consequences of ADT and 
sarcopenia (91, 92), including the reversal of the loss of muscle mass and strength (55, 
Figure 1. The reduction in musculoskeletal fitness with aging and ADT 
and the potential role of strength training to increase musculoskeletal 
fitness and maintain reserve capacity in ADT-treated men. Adapted 
from Galvao et al. (66). 
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90, 169), muscle power (42, 160), bone loss (138, 171, 172), regional fat deposition (198, 
215), and functional declines (63, 76, 79). 
 Currently, there are only two published studies that address the independent 
effects of supervised ST in patients undergoing ADT (61, 176), though other relevant 
ADT investigations exist (115). Segal et al. (176) specifically examined basic aspects of 
muscle function in patients undergoing ADT before and after a 12 week ST program 
compared to a non-exercising control group. Men who underwent ST significantly 
improved their strength, muscle endurance, and QoL compared to the control group. No 
changes in body composition were observed. However, no direct assessment of muscle 
strength was performed, body composition was estimated using skinfolds, and muscle 
size, muscle power, bone mass, or physical function were not reported. Following up on 
this initial study, Galvao et al. (61) reported improvements in strength and functional 
abilities after 20 weeks of ST in a study of ten PCa patients. No change in total lean mass 
or BMD was observed, and the study did not include blacks. Kvorning et al. (115) 
observed that strength and muscle mass gains were attenuated in young men on ADT 
when compared to healthy controls. However, despite this finding, it is presently unclear 
whether the suppression of testosterone in those with PCa undergoing ADT would 
prevent or limit ST-induced improvements in muscle mass and power as few studies are 
available to support or reject such a hypothesis and none have examined this in black 
men on ADT. 
 Muscle power is of particular interest due to its strong relationship with activities 
of daily living performance (9, 80, 135). Our group has reported significant 




observed a significant portion of the variability in physical functioning improvements 
with ST are accounted for by improvements in muscle power (76). Consequently, it was 
hypothesized that muscle power is an important contributor to QoL for men with PCa.  
 The ability of the muscle to undergo hypertrophy under castrate levels of 
testosterone is also unresolved, as a study in rats found no effect of an exercise-like 
stimulus on muscle mass in castrated vs. control animals (152) while another using 
electrical stimulation reports that muscle hypertrophy was suppressed in rats being 
administered androgen receptor antagonists (96). Reports in human populations are 
limited. We are aware of only one report that directly assessed changes in muscle size 
with ST in PCa patients on ADT (74). In this pilot study, five PCa patients on and five 
not on ADT completed 12 weeks of resistance exercise using recumbent, high force 
eccentric ergometry (74). The PCa patients who were on ADT showed no significant 
increase in muscle volume, whereas, those who were not on ADT experienced muscle 
hypertrophy. Although the differences between groups did not reach statistical 
significance with this sample size, it does raise the question about whether ADT might 
prevent or blunt the typical hypertrophic response to ST. It should not be assumed that 
the same changes that result from ST in normal healthy volunteers will necessarily occur 
in PCa patients on ADT.  
 Thus, the purpose of this study was 1) to examine the effects of ST on common 
musculoskeletal and body composition side effects of ADT in black men on ADT, 2) to 
compare ST responses of black PCa patients on ADT to those of black healthy reference 
controls, and 3) to determine if changes in musculoskeletal health and body composition 






PCa patients were recruited by referrals from the Veteran Affairs Medical Centers 
in Washington, DC and Baltimore, MD and through advertisements sent to the general 
population and support groups in the communities that surround the University of 
Maryland campus. In addition, local urology physicians in the vicinity were targeted for 
referrals. An overview of the recruitment strategy is provided in Figure 2. 
Potential patients were recruited from local cancer registry, Veteran Affairs 
hospitals, support groups, and local urologists 
Potential subjects responding to recruitment letter (N=44) 
Excluded from participating due to: 
Not on ADT (N=8) 
Too busy (N=4) 
Uncontrolled PCa (N=2) 
No medical clearance (N=4) 
Unwilling to travel to campus (N=2) 
No response to initial call (N=2) 
Eligible for orientation (N=22) 
 
Declined after orientation (N=3) 
Underwent baseline testing (N=19) 
Completed all aspects of the study (N=17) 
Dropped out of study due to: 
Hypotension during exercise (N=1) 
Kidney stones (N=1) 




To be eligible to participate, subjects needed to currently be on ADT and to 
remain on it throughout the duration of the study. Exclusionary criteria included severe 
cardiovascular disease, musculoskeletal diseases that cause severe joint pain at rest or 
upon exertion, having any condition that is likely to be aggravated by muscular exertion, 
Type I diabetes, history of bone fragility fractures, being unable to engage safely in mild 
to moderate exercise, such as independently walking up at least one flight of stairs or 
walking two blocks on level ground, unwilling to travel to campus for training, or lack of 
medical clearance from their primary care physician.  
Subjects 
Nineteen sedentary men ages 58 to 80 volunteered to participate in the study. 
Most subjects were sedentary in nature, defined as not having participated in a structured 
exercise program on a regular and consistent basis, with the exception of regular walking. 
Only one subject had participated in a ST program in the six months preceding 
enrollment in the study and analyses run with and without his data did not affect the 
results. Of the 19 subjects who completed baseline testing, 17 completed all follow-up 
testing.  
All subjects underwent an initial phone screening interview, a detailed medical 
questionnaire, and also received medical clearance from their primary care physician. A 
PCa history questionnaire was also completed, which included diagnosis date, treatment 
types, and treatment duration. Subjects on medications in addition to ADT were 
requested to maintain the dosage throughout the study. All subjects maintained stable 
body weight, defined as within 5%, (monitored weekly) and were asked to maintain their 




medication use, was verbally confirmed on a regular basis. After all methods and 
procedures were explained, subjects read and signed the informed consent which was 
approved by the University of Maryland Institutional Review Board.  
A reference control group was obtained from a previous study in our laboratory. 
This group consisted of healthy, inactive black men who completed a 10 week unilateral 
ST program of the knee extensors designed to optimize gains in leg muscle hypertrophy.  
They were selected as a comparison group representing ideal responses to ST.  The 
inclusion/exclusion criteria and screening processes used for  subjects in the reference 
control group have been described previously (42). 
Strength Testing 
One repetition maximum (1RM) strength testing for the knee extension, chest 
press, and leg press were performed at baseline and after the ST program using Keiser air 
powered machines (Keiser Corporation Inc, Fresno, CA, USA) via standardized protocols 
(42, 76). The 1RM was achieved by gradually increasing the resistance after each 
successful repetition until the maximal load was obtained for each exercise, typically 
requiring eight to 12 trials to attain the 1RM. Prior to baseline testing, two sessions were 
performed with light resistance to familiarize the subjects with the equipment, to help 
control for the large 1RM strength gains that commonly result from skill acquisition 
during the initial stages of training, and to aid in injury prevention and reduce muscle 
soreness following the testing bout. The knee extension 1RM was assessed unilaterally 
while the chest and leg press were assessed bilaterally. The reference control subjects 
completed 1RM testing only for the knee extensors, but otherwise followed identical 





 Localized muscle fatigue was assessed using a repetition test on the chest and leg 
presses in the PCa patients. At the completion of the respective 1RM test, subjects rested 
for five minutes before performing as many consecutive repetitions as possible at 70% of 
baseline 1RM until failure occurred. Failure was defined by either pausing to rest at any 
point during the test or the inability to fully complete the final repetition. The same 
absolute load was replicated after the ST protocol. An increase in repetition number with 
ST constituted a decrease in localized fatigue and improved muscle endurance. 
Power Testing 
Peak power, peak velocity, and peak torque of the knee extensors were evaluated 
at baseline and after ST for all subjects on a Keiser A-430 air-powered machine designed 
specifically for muscle power assessment using methods described previously (42). After 
performing three familiarization trials, subjects completed three repetitions per leg at 
three different intensities, 50, 60 and 70% of their knee extension 1RM, in an alternating 
fashion for a total of nine repetitions. The rest period between each trial at a given load 
was one minute and two minutes of rest separated each increase in resistance. The peak 
power, velocity, and torque values were then selected for each relative intensity. An 
attempt was made to find an absolute load that could be replicated from baseline testing. 
If a relative load after ST was within 5% of a baseline load, then the same relative load 
was replicated from baseline testing. This typically occurred at 70% of 1RM at baseline 
and at 50 or 60% of 1RM after ST. If no such load could be found, an additional set of 






Fat free mass (FFM), % fat, bone mineral content (BMC), and BMD for all 
subjects was estimated at baseline and after ST by dual-energy X-ray absorptiometry 
(DEXA) using fan-beam technology (model QDR 4500A, Hologic, Waltham, 
Massachusetts, USA) as described previously (42). Upper, lower, and appendicular body 
composition were determined in the PCa patients, in addition to overall body 
composition. The ischial crest of the pelvis was used as the boney landmark to 
differentiate between upper and lower body segments. Appendicular body composition 
was the sum of the lower body combined with the sum of the arms, defined using the 
medial aspect of the humeral head as the cutpoint to differentiate the arms from the trunk 
(62). Coefficients of variation (CV) for all DEXA measures of body composition were 
determined using scans from ten subjects, each who were scanned three consecutive 
times with body repositioning. The CV for FFM was <1.0% and 1.0% for % fat (42). The 
scanner was calibrated daily against a spine calibration block, a small step phantom, and 
an empty table background scan (Radiograph Uniformity Test). 
To quantify leg muscle volume (MV) in the PCa patients, computed tomography 
(CT) (GE Lightspeed Qxi, General Electric, Milwaukee, Wisconsin, USA) imaging of the 
thighs was performed at baseline and after ST program using previously described 
methods (207) and was modified to include all leg musculature. Final MV was calculated 
using the truncated cone formula (197). Briefly, MV was calculated by manually 
outlining the cross-sectional area of the deep fascial plane outlined every 40 mm from the 
first section closest to the superior border of the patella to a point where the fascia was no 




superior cross-sectional slice. Care was taken to ensure that the same number of sections 
proximal from the patella was measured for a particular subject before and after ST to 
ensure within-subject measurement replication. Coefficients of variation were calculated 
using repeated measures of selected axial sections of one subject on two separate days. 
The within-investigator reliability average was <1.0% and the between investigator 
average was 2.6%. The MV values for the reference controls included only the 
quadriceps muscle groups and followed procedures described previously  (207). All other 
procedures for assessing MV were identical to those described for the PCa patients. 
Similar to thigh MV, SCF cross-sectional area was assessed in all subjects by 
additionally outlining the entire thigh and subtracting the area inside the deep fascial 
plane from the thigh area of a single CT slice at the midpoint of the thigh. The IMF cross-
sectional area was distinguished by excluding the bone marrow fat from the deep fascial 
plane (71). The IMF was then segmented into a separate image, in which it was identified 
on the basis of Hounsfield units, where IMF ranged from -190 to -30, as previously 
described (71). The average within-investigator CV were both <1.0% and the between-
investigator average was 2.8% for SCF and 4.3% for IMF, respectively. For all analyses, 
technicians were blinded to subject identification, date of scan, and training status for 
both baseline and post training scans. 
Physical Function Testing 
 Physical function was assessed at baseline and after ST in PCa patients using six 
different functional tests: the 6m usual and rapid walks, a timed up and go test, the 
number of chairs stands that could be completed in 30 seconds, a stair climb, and a 400m 




described previously (76) with slight modification to the chair stand protocol. All trials 
were preceded by a practice trial and were performed in duplicate with the fastest time 
being recorded, with the exception of the 30 second chair stands and 400m walk.  
6-m Walks. Habitual and maximal walking speed was assessed by measuring the 
time it took subjects to cover a 6-m course. To avoid bias from deceleration, subjects 
were instructed to walk to a mark 1.25 m beyond the 6-m line. The rest interval between 
trials was 30 seconds and one minute between tasks.  
Timed Up and Go. The 43-cm chair used in the chair stands test was again used in 
the up and go test. In this task, subjects were required to rise from a seated position, walk 
2.44 m (8 feet) around a cone, and return to the seated position. The rest interval between 
trials was one minute. 
Chair Stands. A hard-seated, straight-backed, armless chair that was 43 cm in 
height was used to evaluate chair stand performance. Subject began the task in a seated 
position with arms folded across the chest. Over the course of 30 seconds, the number of 
successfully completed repetitions was measured. To be considered complete, the legs 
had to be fully extended before the 30 seconds had elapsed. To count as a complete 
repetition, subjects were required to stand fully and to sit completely and the final 
repetition needed to be completed prior to time expiring. This was monitored visually by 
the investigators. A single trial was performed and the rest interval following this task 
was five minutes. 
Stair Climb. Stair climbing ability was assessed by timing subjects as they 
climbed a single flight of nine stairs. Each step was 19 cm in height. The standardized 




were required to place at least one foot on each step, and no running or skipping of steps 
was permitted. The rest interval between trials was one minute. 
400m Walk. 400m walk time was used as index of muscle endurance. Subjects 
completed 2.5 laps on an indoor synthetic surfaced track. A single trial was performed. 
Blood Sampling and Biomarkers 
 Venous blood was sampled from PCa patients at baseline and after ST following 
an overnight fast. Samples were collected in K2 EDTA coated and uncoated tubes for 
plasma and serum separation, respectively (Becton Dickinson, Franklin Lakes, NJ, USA). 
Hematocrit and hemoglobin (HemoCue Hb 201+ Analyzer, Lake Forrest, CA, USA) 
were measured in triplicate prior to all tubes being centrifuged at 3000g for 10 minutes at 
4°C. The supernatant was removed and stored in 0.5 mL aliquots at -80°C until analysis. 
Prostate specific antigen (PSA) levels were determined in duplicate using a commercially 
available kit (R & D Systems Quantikine® Human Kallikrein 3/PSA ELISA, 
Minneapolis, MN, USA) and following the manufacturer’s instructions. A set of low, 
medium, and high standards along with two negative controls were used to confirm that 
the assay worked correctly. The manufacturer reports an intra-assay CV of 5.2% and an 
inter-assay CV of 6.3% with a mean minimal detectable dose of 0.030 ng/mL. Free 
testosterone was measured in duplicate using a radioimmunoassay (Beckman Coulter, 
Brea, CA, USA) at the Baltimore Veterans Affairs Hospital following the manufacturer’s 
instructions. The manufacturer reports an intra-assay CV of <6.2%, an inter-assay CV of 
<9.7%, and a sensitivity of 0.18 pg/mL. High and low standards and positive and 




Generalized Fatigue Perception and Quality of Life 
 The Brief Fatigue Inventory© (BFI) (University of Texas MD Anderson Cancer 
Center, Houston, TX, USA, used with permission) and the Functional Assessment of 
Cancer Therapy-Prostate (FACT-P) (FACIT.org, Elmhert, IL, USA, used with 
permission) were measured at baseline and after ST in PCa patients as indicators of 
generalized fatigue perception and QoL, respectively. The internal consistency and 
validity for the BFI has previously been reported, with a Cronbach α coefficient value of 
0.96 (137). The BFI is highly correlated with other fatigue questionnaires (93, 137), 
including the Profile of Mood States (POMS) and FACT-Fatigue. The FACT-P is an 
extension of the 27 item FACT-General questionnaire, which consists of four primary 
QoL domains (Physical, Social, Emotional, and Functional Well-Being). An additional 
12 questions specific to PCa symptoms and treatment designate this questionnaire as the 
FACT-P. The questionnaire demonstrates high internal consistency and validity with 
Cronbach α ranging from 0.60 – 0.83 for the four general QoL domains and 0.65 – 0.69 
for the Prostate specific subsection from 0.65 – 0.69 (51). The clinically meaningful 
change for the overall FACT-P score is 6-10 units (31). 
Near the end of the training period, one subject began iron supplementation 
therapy for anemia after complaining of fatigue. This violated the guidelines of the study 
protocol. Therefore, this subject was removed from the data analysis for BFI and FACT-
P. 
Strength Training Protocol 
 The training program for the PCa patients consisted of 12 weeks of ST, three days 




Corporation Inc., Fresno, CA, USA). Keiser equipment was selected for training due to 
its ease in changing the resistance without interrupting the cadence of the exercise. 
Exercises included unilateral knee extension, chest press, seated row, seated hamstring 
curl, abdominal crunch, and leg press. Upon arrival to the laboratory, subjects sat quietly 
for five minutes and had resting blood pressure measured prior to completing a brief 
cycling warm up. Subjects then performed two sets of each exercise. The first set was a 
warm-up at 50% of the training load on each particular day. A single training set of 15 
repetitions was performed at each subject’s five repetition maximum (5RM), which was 
continuously adjusted throughout the training program to reflect strength gains. To 
complete the training set, the first four to five repetitions were performed at the current 
5RM value, then the resistance was lowered just enough to complete one or two more 
repetitions before reaching muscular fatigue. This process was repeated until all 
repetitions were completed. The resistance was adjusted accordingly for the following 
training session in order to ensure each repetition was performed using the proper 
resistance and form through the full range of motion. Upon completion of all training 
sets, subjects completed each session with a full body stretching routine. Training 
sessions were conducted individually or in small groups under direct supervision to 
provide motivation, to maintain intensity, and to ensure exercises were completed safely 
using a full range of motion. All sets and weights were recorded and the logs were 
checked weekly. The attendance compliance for all training sessions for the PCa patients 
was 94.6 ± 1.6%. 
 The ST program for the reference controls followed identical warm up procedures 




extensors of one leg (trained leg) three days per week for 10 weeks. This unilateral 
protocol was designed to combine heavy resistance with high volume while eliciting 
near-maximal effort on all repetitions and has been effective in increasing 1RM and MV 
of older adults (42, 98, 197, 207). All subjects completed a warm up set of five knee 
extension repetitions at 50% of the daily training load before completing training sets of 
five, 10, 15, and 20 repetitions at their 5RM, which was adjusted continuously throughout 
training. The rest intervals between the training sets were 90, 150, and 180 seconds, 
respectively. The attendance compliance for all training sessions for the PCa patients was 
90.9 ± 1.8%. 
Statistical Analyses 
Data were analyzed using SPSS statistical software (SPSS Inc., Chicago IL, 
USA). To assess the role of ST on musculoskeletal and body composition side effects of 
ADT in PCa patients, paired t-tests were used to determine the change with ST for all 
variables. The t-tests were one-tailed, based on directional hypotheses. Next, mixed 
model repeated measures (group x training) ANOVAs were used to compare PCa patient 
responses to ST with those of the healthy reference controls using the trained leg of the 
reference control group for all comparisons. When significant interactions were observed, 
post hoc analyses were used to locate specific differences. If no interaction was observed, 
the between group differences (PCa vs. reference controls) were examined. Lastly, 
correlation and multiple regression analyses were performed to determine associations 
and predictive power of changes in physical function, fatigue, and QoL to those of 
muscle function and body composition. Variables with the highest correlations were used 




variables in the regression models were the change scores that were significantly different 
from baseline for physical function task times, BFI, and FACT-P. All data were 
expressed as means ± SEM. Statistical significance was accepted at P < 0.05 for all 
ANOVA and P < 0.10 for all regression models due to the lack of orthogonality of the 
independent regression variables and limited sample size. 
Post-hoc power analyses were performed using G*Power 3.1 (53) based on effect 
sizes calculated using the original standard deviation, rather than the pooled standard 
deviation. This was done to avoid overestimation of the effect sizes due to smaller pooled 
standard deviations observed in repeated measures designs. The majority of the primary 
dependent variables were sufficiently powered, in excess of 0.90, including all measures 
of muscle strength and power and most of the physical function tasks. The statistical 
power for FFM, MV, BFI, and FACT-P scores were lower with values ranging from 0.22 
to 0.50. A complete list of sample sizes, mean differences, standard deviations, effect 






 The characteristics for the 17 PCa patients and the 20 reference controls are 
described in Table 1. The PCa patients were borderline anemic, obese, and had variable  
Table 1. Baseline and after ST physical characteristics of PCa patients and reference 
controls. 
  PCa (N=17) Reference Controls (N=20) ‡ 
  Baseline After ST Baseline After ST 
Age (y) † 67 ± 2 - 61 ± 2 - 
Height (cm) 172.8 ±  1.7 - 174.7 ± 2.0 - 
Mass (kg) # 96.5 ± 4.7 97.9 ± 4.9 *  91.0 ± 3.2 91.2 ± 3.1 
BMI (kg/m2) 32.3 ± 1.2 32.7 ± 1.3 29.9 ± 1.0 30.0 ± 1.0 
% Fat  † 31.4 ± 1.4 30.7 ± 1.5 * 26.9 ± 0.9 26.3 ± 0.9 * 
Fat Mass (kg) † 31.2 ± 3.0 31.1 ± 3.2 24.8 ± 1.6 24.3 ± 1.5 
FFM (kg) # 62.4 ± 1.8 64.1 ± 1.8 *** 66.3 ± 1.9 66.9 ± 1.8 * 
BMC (kg) 3.1 ± 0.2 3.0 ± 0.2 2.9 ± 0.1 2.9 ± 0.1 
BMD (g/cm2) 1.26 ± 0.05 1.24 ± 0.05 - - 
Free T (pg/mL) ¥ 1.4 ± 0.5 2.9 ± 1.4 - - 
PSA (ng/mL) 0.58 ± 0.15 0.32 ± 0.15 - - 
Hemoglobin (g/dL) 12.9 ± 0.3 12.7 ± 0.3 - - 
Hematocrit (%) 38.3 ± 0.8 37.8 ± 0.9 - - 
PCa Diagnosis (d) - 2958 ± 491 - - 
Length of ADT (d) - 1449 ± 334 - - 
LHRHa (%) 93.8 - - - 
Anti-A (%) 31.3 - - - 
Radiation (%) 41.2 - - - 
Prostatectomy (%) 29.4 - - - 
‡ Healthy, older black men who underwent a unilateral knee extensor ST protocol and 
are provided as an example of optimal training conditions in subjects of similar age and 
race.  
¥ Free T means and standard errors were calculated using nine PCa patients. The 
remaining eight patients had undetectable levels.  
BMC = Bone Mineral Content; BMD = Bone Mineral Density; FFM= Fat Free Mass; 
Free T = Free Testosterone; PSA = Prostate Specific Antigen; LHRHa = Luteinizing 
Hormone Releasing Hormone agonist; Anti-A = Anti-Androgen treatment 
# Trend for interaction of group x training (P < 0.10) 
† Significant effect of group (P < 0.05) 
* P < 0.05 




lengths of ADT, ranging from less than one to 12.4 years. They experienced a significant 
increase in body mass (1.5 ± 0.5%, P = 0.023) and a trend for an increase in BMI (1.2 ± 
0.5% P = 0.057) and a significant decline in % fat (P = 0.013) with ST. All PCa patients 
were on ADT throughout the study, as confirmed by assessing free testosterone levels 
both before and after ST. There was no change in free testosterone or PSA with ST. 
When the response to ST was compared to the reference control group, similar responses 
were observed for most variables. However, there was a trend for differences in body 
mass and FFM with ST (P < 0.10) favoring the PCa group. There were also significant 
between group differences for % fat and total fat mass (both P < 0.05), which were 
significantly lower in the reference controls. 
Muscle Strength and Endurance 
 Figure 3 shows significant gains in unilateral 1 RM strength for the knee 
extensors (R leg: 27.8 ± 3.4%; L leg: 16.6 ± 3.3%, both P < 0.001), chest press (18.4 ± 
3.3%, P < 0.001), and leg press (22.5 ± 3.3%, P < 0.001) with training in the PCa 
patients. Substantial improvements were also observed in chest press and leg press 
muscle endurance (64.5 ± 6.8% and 109.7 ± 40.2%, respectively both P < 0.001, Table 
2). Reference controls also significantly improved their knee extensor 1 RM values (P < 
0.001) and had a greater strength levels than PCa patients (P < 0.001), but the increases 
were not significantly different than those of the PCa group. 
Muscle Power 
 Figure 4 displays significant increases in absolute (R leg: 15.1 ± 3.5%; L leg: 13.5 
± 3.6%, both P < 0.001) and relative muscle power of the knee extensors in PCa patients 




there were primarily only trends for increased power with ST in the reference controls. 
Nevertheless, there were no significant differences in the response to ST between the 
groups, though the reference controls showed greater power output at all loads (all P < 
0.01). Training also significantly increased the peak torque achieved during power testing 
within all loads for PCa patients (all P < 0.05, Table 2). Absolute peak velocity 
significantly increased with ST (R leg: P < 0.001; L leg: P = 0.018) but remained 
Figure 3. Baseline and after ST muscle strength (1RM) levels in PCa 
patients (N=14) and reference controls (N=15). The left Y axis is scaled 
in Kgs for the Knee Extension (KE) and Chest Press while the right Y 
axis is scaled in Kg for the Leg Press. 
‡ Healthy, older black men who underwent a unilateral knee extensor 
ST protocol and are provided as an example of a reference control 
population of subjects of similar age and race 
† Significant effect of group (P < 0.05) 































































Figure 4. Baseline and after ST absolute and relative peak power 
output in PCa patients (N=15) and reference controls (N=14). 
Abs = Absolute PP; PP = Peak Power at 50, 60, and 70% of 1RM  
The left Y axis is scaled in Watts for the PCa patients while the right Y 
axis is scaled in Watts for the reference controls. 
‡ Trained leg from the reference control group. 
† Significant effect of group (P < 0.05) 
* Significantly different from baseline value (P < 0.05) 
** Significantly different from baseline value (P < 0.01) 
*** Significantly different from baseline value (P < 0.001) 
 
unchanged at the relative loads with one exception (R leg: 70% load), suggesting that 
both peak torque and movement velocity contributed to the gains in absolute power with 
training while increased peak torque appears to be the principle factor at relative loads. 
When compared to reference controls, there were no differences in the response to ST 
between groups for the increases in peak torque, whereas the increases in absolute peak 





Table 2. Baseline and after ST muscle endurance, torque, velocity, and thigh fat values in 
PCa patients and reference controls. 
  PCa (N=15-16) Reference Controls (N=14) ‡ 
  Baseline After ST Baseline After ST 
Chest Press End 12.1 ± 0.6 19.9 ± 1.3 *** - - 
Leg Press End 17.6 ± 2.4 36.9 ± 3.7 *** - - 
PT Abs (N) 188.3 ± 10.0 191.6 ± 10.3 ** 148.4 ± 27.5 151.5 ± 27.7 
PT 50 (N) 171.2 ± 5.3 200.7  ± 8.1 *** 136.9 ± 23.6 156.2 ± 25.5 *** 
PT 60 (N) 200.4  ± 8.8 229.6  ± 10.0 * 162.0 ± 28.6 183.7 ± 30.3 *** 
PT 70 (N) 229.8  ± 10.8 265.1  ± 11.9 ** 176.3 ± 32.0 200.7 ± 34.6 *** 
PV Abs (rads/sec) # 5.1 ± 0.2 a 5.7 ± 0.2 ** 6.2 ± 0.2 6.2 ± 0.2 
PV 50  (rads/sec) † 5.6 ± 0.2 5.5 ± 0.2 6.4 ± 0.2 5.8 ± 0.3 ** 
PV 60 (rads/sec) 5.0 ± 0.2 4.8 ± 0.2 5.6 ± 0.3 4.9 ± 0.2 ** 
PV 70 (rads/sec) 4.5 ± 0.2 4.1 ± 0.2 * 4.8 ± 0.2 4.2 ± 0.3 * 
SCF (cm2) † 116.6 ± 20.8  116.8 ± 21.0 57.0 ± 5.8 57.6 ± 5.5 
IMF (cm2) 7.9 ± 0.9 7.6 ± 1.0 6.3 ± 0.7 6.2 ± 0.6 
‡ Healthy, older black men who underwent a unilateral knee extensor ST protocol and are 
provided as an example of optimal training conditions in subjects of similar age and race.  
End = Endurance Repetition Test; PT Abs = Absolute Peak Torque of the knee extensors 
during power testing; PT = Peak Torque at 50, 60, and 70% of KE 1RM; PV = KE Peak 
Velocity; SCF = Subcutaneous Fat; IMF = Intermuscular Fat 
# Significant interaction of group x training (P < 0.05) 
a Significantly different between groups (P < 0.001) 
† Significantly main effect of group (P < 0.05) 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
 
Total and Regional Body Composition 
  Total body composition significantly improved with ST. Despite the ablation of 
endogenous testosterone from ADT, significant increases in FFM were observed in the 
upper body (2.2 ± 0.5%, P = 0.0026), lower body (3.8 ± 1.0%, P = 0.0014), appendicular 
(3.6 ± 0.9%, P = 0.0011), and in the total body (2.7 ± 0.4%, P < 0.001, Table 1). There 
were no significant changes in BMC, BMD or fat mass in any of the body regions. Total 


























Figure 5. Baseline and after ST thigh MV in PCa patients (N=16) and 
reference controls (N=20). The left Y axis is scaled in cm3 for the 
whole thigh MV for the PCa patients while the right Y axis is scaled 
in cm3 for the MV of only the knee extensors of the reference 
controls. 
‡ Trained leg from the reference control group provided as an 
example of optimal training conditions for muscle hypertrophy.  
† Significant effect of group (P < 0.05) 
*** Significantly different from baseline value (P < 0.001) 
 
the increased total body FFM. There was a trend for ST to increase FFM in reference 
controls (0.9 ± 0.6%, P = 0.051).  
 The changes in regional body composition are presented in Figure 5. Thigh MV 
increased significantly in both legs of the PCa patients and the trained leg of the reference 
controls (R leg: 6.4 ± 0.8%; L leg: 6.5 ± 0.9%; Trained Leg: 9.9 ± 1.1%, all P < 0.001), 
but there was no difference in the response to ST between groups. PCa patients displayed 





the measurement of MV. Finally, there was no significant change in SCF or IMF with ST 
in either group, but PCa patients had substantially greater SCF values (P = 0.005) than 
the reference controls (Table 2). 
Physical Function 
 Figure 6 shows significant improvements in all indicators of physical function 
with ST. The largest gain in function was observed in the chair stands (20.3 ± 4.3%, P < 




























Figure 6. Physical function at baseline and after ST in PCa patients 
(N=17). The left Y axis is scaled in seconds for the Usual and Rapid 
walk, Up and Go, Stair Climb, and 400m walk tests while the right Y 
axis is scaled for the number of successful Chair Stands in 30 
seconds. 
* Significantly different from baseline value (P < 0.05) 
** Significantly different from baseline value (P < 0.01) 

















improvements were observed in the remaining functional tasks, but all remained 
significant (Range: 6.7 – 8.0%, all P < 0.05). The inclusion of length of ADT treatment 
as a covariate had no significant effect on all but two measures of  physical function, i.e., 
6m Rapid and 400m Walks, and did not change the overall interpretation of the results. 
Therefore, the raw values were reported. 
Fatigue Perception and QoL  
Fatigue perception and QoL data are presented in Figure 7. Fatigue perception 
decreased significantly with ST (P = 0.011). The overall FACT-P score significantly 
Figure 7. Fatigue perception and QoL at baseline and after ST in PCa 
patients (N=17). The left Y axis is scaled for the BFI score and each 
individual subsection of the FACT-P while the right Y axis is scaled 
for the composite FACT-P score.  
* Significantly different from baseline value (P < 0.05)




































increased as a result of ST (P < 0.05), as did the Physical Well-Being subsection (P < 
0.01), while there was a trend for improvements in the Functional Well-Being 
subsections (P = 0.069).  
Physiological Traits, Physical Function, and QoL Correlations 
 To establish the initial associations between baseline and ST-induced changes in 
muscle function, body composition, fatigue perception, physical function, and QoL, 
correlation matrices were established (Tables 3 - 5). At baseline, length of ADT treatment 
was significantly correlated with BFI and physical function, such that longer treatment 
resulted in greater fatigue and lower function. Higher baseline body mass, BMI, and total 
and regional fat masses were positively correlated with baseline BFI and physical 
function, while strength and power were negatively correlated with BFI and physical 
function (all P < 0.05, Table 3). Neither MV or FFM were consistently correlated with 
functional performance or fatigue perception at either baseline or with ST. The change 
scores for fatigue and physical function remained correlated with length of ADT 
treatment, in addition to changes in body mass and BMI (all P < 0.05, Table 4). The 
increases in absolute peak power and chest press 1RM were also consistently correlated 
with improved physical function (P < 0.05).  
 Overall FACT-P score, along with the Physical and Functional subsections, were 
significantly correlated  with  the  BFI  at baseline for the PCa patients  (Pearson r values:  
-0.668, -0.676, and -0.693, all P < 0.01, Table 5). In addition, all estimates of physical 
function, except for 6m usual walk, were significantly correlated with QoL (P < 0.05). 
However, BFI change scores were not correlated with the Physical and Functional 




overall FACT-P score with ST. The correlations between changes in physical function 
and FACT-P were inconsistent as well, as only stair climb improvement was significantly 
correlated with changes in FACT-P scores (all P < 0.05). 
Table 3. Correlations between BFI, Physical Function, Muscle Function, and Body 
Composition at baseline in PCa patients. 
 BFI Usual Rapid Up & Go Chair Stair 400m 
ADT days 0.688** 0.018 0.353 0.522* -0.634** 0.491* 0.533* 
Mass 0.529* 0.087 0.488* 0.861** -0.673** 0.762** 0.759** 
BMI 0.403 0.069 0.525* 0.748** -0.471* 0.699** 0.803** 
% Fat 0.453* -0.151 0.353 0.680** -0.583** 0.679** 0.706** 
Fat 0.571* -0.005 0.481* 0.842** -0.683** 0.770** 0.784** 
FFM 0.362 0.231 0.387 0.743** -0.558* 0.601** 0.585* 
KE 1RM -0.004 -0.074 0.054 -0.318 0.441* 0.001 -0.130 
CP 1RM -0.367 -0.272 -0.166 -0.555* 0.727** -0.283 -0.418 
LP 1RM -0.270 -0.349 0.012 -0.138 0.351 -0.090 -0.030 
CP End -0.082 -0.093 0.208 -0.061 0.116 -0.099 -0.106 
LP End -0.114 -0.152 0.316 0.289 -0.332 0.462* 0.110 
PP Abs -0.604* -0.064 -0.527* -0.474* 0.567* -0.454 -0.532* 
MV 0.092 0.230 0.101 0.515* -0.323 0.394 0.433 
SCF 0.705** 0.297 0.484* 0.732** -0.474* 0.528* 0.606** 
IMF 0.468* -0.043 0.330 0.694** -0.664** 0.584** 0.615** 
ADT days = length of ADT; BMI = Body Mass Index; FFM = Fat Free Mass; KE 
1RM = Knee Extensor Maximal Strength; CP = Chest Press; LP = Leg Press; CP/LP 
End = Endurance Test; PP Abs = Knee Extensor; Absolute Peak Power; MV = 
Muscle Volume; SCF = Subcutaneous Fat; IMF = Intermuscular Fat; Usual = 6m 
Usual Walk; Rapid = 6m Rapid Walk; Up & Go = Timed Up and Go; Chair = Chair 
Stands Task; Stair = Stair Climb; 400m = 400m Walk 
* P < 0.05 
** P < 0.01 
 
Regression Analysis 
 The results of the regression analysis are displayed in Table 6. The model for 
change in usual walk time was not significant, but all others were significant (P < 0.10) 
and had R2 values ranging from 0.21 to 0.66. Based on sample size limitations, only two 




treatment length in nearly all models. The exclusion of ADT length in the physical 
function regression models resulted in a loss of statistical significance. 
 
Table 4. Change score correlations between BFI, Physical Function, Muscle Function, 
and Body Composition.        
 BFI Usual Rapid Up & Go Chair Stair 400m 
ADT days -0.434* -0.303 -0.563* -0.402 0.261 -0.405 0.516* 
Mass 0.022 0.005 -0.488* -0.433* 0.168 -0.489* 0.623** 
BMI 0.149 0.041 -0.495* 0.123 0.177 -0.126 0.509* 
% Fat -0.238 -0.005 -0.063 -0.244 -0.132 -0.058 0.423 
FFM 0.277 0.127 -0.302 0.010 0.232 -0.253 0.164 
KE 1RM 0.199 0.071 0.276 -0.094 -0.248 -0.102 -0.144 
CP 1RM -0.137 -0.416* -0.494* -0.667** 0.264 -0.640** 0.207 
LP 1RM -0.102 -0.103 -0.111 -0.433* 0.165 -0.526* 0.250 
CP End -0.131 -0.368 -0.382 -0.521* 0.382 -0.618** 0.252 
LP End -0.415 -0.160 0.224 0.167 -0.165 -0.113 0.079 
PP Abs -0.146 0.091 -0.736** -0.358 0.276 -0.524* 0.156 
MV -0.459* -0.061 -0.053 0.116 -0.006 -0.112 0.510* 
ADT days = Length of ADT; BMI = Body Mass Index; FFM = Fat Free Mass; KE 
1RM = Knee Extensor Maximal Strength; CP = Chest Press; LP = Leg Press; CP/LP 
End = Endurance Test; PP Abs = Knee Extensor Absolute Peak Power; MV = Muscle 
Volume; SCF = Subcutaneous Fat; IMF = Intermuscular Fat; Usual = 6m Usual Walk; 
Rapid = 6m Rapid Walk; Up & Go = Timed Up and Go; Chair = Chair Stands Task; 
Stair = Stair Climb; 400m = 400m Walk 
* P < 0.05 
** P < 0.01 
 
Adverse Events 
 There were no adverse events during any of the testing sessions and only one 
instance of hypotension and dizziness during ST. After consulting with his personal 






Table 5. Correlations between QoL, BFI, and Physical Function at baseline and after ST 
in PCa patients. 
 Baseline  Changes with ST 
 Physical Function Total  Physical Function Total 
BFI -0.676** -0.693** -0.668**  -0.157 -0.295 -0.408 
Usual 0.134 -0.074 -0.053  0.037 -0.232 -0.086 
Rapid -0.564* -0.687** -0.678**  -0.001 -0.152 -0.312 
Up & Go -0.548* -0.577** -0.623**  -0.332 -0.356 -0.281 
Chair 0.616** 0.627** 0.617**  -0.057 0.119 0.023 
Stair -0.734** -0.826** -0.840**  -0.440* -0.545* -0.546* 
400m -0.647** -0.686** -0.692**  0.189 0.434 0.238 
BFI = Brief Fatigue Inventory; Physical and Functional = Subsections of FACT-P; Total 
= Aggregate FACT-P score; Usual = 6m Usual Walk; Rapid = 6m Rapid Walk; Up & 
Go = Timed Up and Go; Chair = Chair Stands Task; Stair = Stair Climb; 400m = 400m 
Walk 
* P < 0.05 











 β coeff P value 
Δ Usual Walk  -  N/S 
     
Δ Rapid Walk  0.66  0.002 
 Δ Absolute PP  -0.004 0.030 
 Δ Mass  -0.095 0.009 
     
Δ Up & Go  0.36  0.083 
 Δ KE 1RM  -0.028 0.139 
 ADT days  -0.001 0.045 
     
Δ Chair Stands  0.33  0.088 
 Δ Absolute PP  0.007 0.441 
 ADT days  0.001 0.052 
     
Δ Stair Climb  0.63  0.002 
 Δ Chest Press Endurance  -0.064 0.004 
 ADT days  1.47E-4 0.012 
     
Δ 400m Walk  0.54  0.020 
 Δ KE 1RM  0.146 0.570 
 ADT days  0.011 0.006 
     
Δ BFI  0.21  0.085 
 Δ MV  -0.070 0.085 
     
Δ FACT-P  0.45  0.022 
 Δ BFI  -0.382 0.086 
 Δ Stair Climb  -19.72 0.024 
Δ = Change in; PP = Peak Power; KE 1RM = Knee Extensor 1RM; ADT = 
Androgen Deprivation Therapy; ADT days = Length of ADT; BFI = Brief Fatigue 






The principal finding from this study is that ST can have highly beneficial effects 
on factors that are adversely affected by ADT in black men being treated for PCa. These 
benefits include substantial gains in muscle power, muscle size, a more favorable body 
composition, improved muscle strength, muscle endurance (fatigue resistance), physical 
function, and lower levels of fatigue perception. ST also had a positive impact on QoL. 
These results confirm previous reports in other racial groups, but also add new 
information to the existing literature by demonstrating for the first time significant 
improvements in muscle power and direct measures of muscle hypertrophy in black men 
on ADT, a previously understudied population. 
Our unique finding of increases in muscle power with ST, both at the same 
absolute and relative loads, has important functional and health implications. Muscle 
power is a key predictor of physical function, to an even greater extent than strength (8, 
9, 38). In support of this conclusion, improvements in power were more closely 
associated with activities of daily living, our surrogate measure of physical function, than 
strength improvements with training. To gain insight into which factors were likely most 
responsible for training-induced increases in muscle power, peak torque and peak 
velocity were examined. Both torque and velocity significantly increased at a given 
absolute power, whereas only torque production increased while velocity remained 
constant at each relative load. These data support the hypothesis that gains in strength are 
the major factor driving the increased power output as higher improvements in torque 




in strength reduces the relative effort required to move an absolute load, shifting the 
force/velocity relationship to faster movement velocities. 
To provide a criterion reference for an effective ST program, we compared the 
subjects from the current study with healthy black reference controls from another study 
in our laboratory. Although the training protocol used for the reference controls was not 
designed to optimize muscle power, it was at least as specific for muscle power 
adaptations as the one used in the current investigation. While the reference controls 
displayed significantly higher power outputs at all loads, these data do not support our 
original hypothesis that men on ADT would have diminished gains in power with ST. To 
the contrary, our PCa patients appear to display a more consistent response across all 
power loads than the reference controls.  
The earliest investigations of ST in men on ADT used skinfolds to assess body 
composition (176). Follow up studies have progressed to include more sophisticated 
techniques, such as ultrasound (61) and magnetic resonance imaging (74). The results of 
these studies are equivocal, with one reporting a significant increase in quadriceps 
thickness (61), whereas the other study did not detect gains in quadriceps MV (74) and 
neither study showed increases in total body FFM. While Hansen et al., (74) did use 
direct measures of hypertrophy, it was unclear whether proper procedures were used to 
ensure replication of slice position, given that no description was provided for how this 
was accomplished. Failure to replicate slice position before and after training can lead to 
significant error. Moreover, these studies did not report the racial or ethnic composition 




Contrary to our hypothesis, treatment with ADT does not appear to blunt the 
ability of the muscle to increase in response to overload as there was no difference in the 
response to ST between groups. However, due to differences in muscle group assessed 
(quadriceps only in reference controls vs. whole thigh muscles in PCa patients), a much 
smaller baseline value in the reference control group favors their larger % change in MV 
response to ST (9.9% vs. 6.4%). No analyses were performed on the % change values. 
Nonetheless, the results clearly show substantial ST-induced muscle hypertrophy in PCa 
patients in the absence of normal levels of testosterone. These findings dispute the long 
held belief that testosterone is necessary to induce muscle hypertrophy and to increase 
strength.  
Another key finding of this study was the significant improvement in total body 
composition. Our study is the first to report increases in total body FFM along with direct 
measurements of local muscle hypertrophy in the same study. Both assessments were 
highly correlated, providing additional support for muscle hypertrophy in men being 
treated with ADT for PCa via two separate methods. These findings stand in contrast to 
most (61, 74, 176), but not all (64), of the previous ST and PCa studies. Using a 
combined training protocol with men on ADT, Galvao et al. (64) reported a 0.7 kg 
increase in total body FFM with exercise in men on ADT, 58% below the increase 
observed in the current study. A lower training frequency (two vs. three time per week) 
and the inclusion of aerobic exercise training in their study may contribute to these 
differences. Our FFM improvement is also similar to what has been reported in the 




 In contrast, Kvorning et al. (115) reported the elimination of strength gains and 
reduced gains in lower body FFM with ST upon the suppression of testosterone in young 
men compared with eugonadal controls. However, the increase in FFM in the control 
group was slightly smaller than the increase in lower body FFM observed in the present 
study, which argues for a non-essential role of testosterone in muscle hypertrophy. This is 
supported by studies that compared the ST response of men vs. women. While 
investigations generally demonstrate a greater increase in MV in men, there are still 
significant gains in women (97, 196, 207). Thus, testosterone appears to enhance muscle 
hypertrophy, but it may not be of paramount importance, as previously suggested (115). 
 Although not essential for muscle hypertrophy, testosterone supplementation can 
increase protein synthesis and muscle mass (54, 200) whereas its suppression decreases 
both (136). Nevertheless, the mechanisms by which testosterone induces hypertrophy are 
currently unclear (15). Some (54, 200, 214), but not all (136) evidence suggests that 
testosterone may interact with insulin-like growth factor one, which can activate 
mammalian target of rapamycin (mTOR), p70S6K, and protein synthesis (69). 
Testosterone may also inhibit glucocorticoid receptor (GR) expression (106) and atrogin-
1 gene expression (219). However, recent data suggest crosstalk between mTOR and the 
GR, as dexamethasone increases transcription of several muscle atrophy genes while 
inhibiting mTOR activity (182). Subsequent activation of mTOR with amino acids 
impeded GR induction of its target genes which were rescued when mTOR was inhibited 
by rapamycin (182). Thus, the loss of the testosterone with ADT and the declines in FFM 
could be explained by a shift in the dynamic balance between protein synthesis and 




muscle through activation of mTOR and thereby increasing protein synthesis, 
independent of sex (48). Inhibition of mTOR blocks protein synthesis increases with 
acute resistance exercise (49), implicating this as a plausible pathway to explain increases 
in FFM with ST in individuals with very low testosterone, e.g., in women or in men on 
ADT. 
 Beyond FFM and MV, body composition was unaltered in the current study. The 
finding of no significant change in fat mass, BMC, or BMD with ST confirms the results 
of previous studies (61, 64). The short duration of this study may have influenced the 
lack of change in bone given that bone remodeling requires a longer time frame than 
muscle hypertrophy (73). Overall, % fat significantly declined, but this is likely due to the 
increase in FFM, resulting in fat being a smaller portion of total body mass. A decrease in 
% fat was also observed in PCa patients undergoing combination training (64). The 
regional body composition measures of SCF and IMF did not change with ST, similar to 
observations from our laboratory in healthy older adults (207). However, SCF was 
significantly higher in men on ADT than in reference controls, but there were no between 
group differences in IMF. The increases in fat infiltration, along with lower muscle mass, 
are possible contributing factors for the reductions in 1RM and physical function which 
are associated with ADT (70, 204). 
 The gains in strength and fatigue resistance as assessed by 1RM and muscle 
endurance testing, respectively, in the current study are supported by previously 
published data (63, 74, 176). Galvao et al. (61) reported significant gains in chest and leg 
press 1RM and muscle endurance at both the midpoint and the end of a 20 week ST 




studies. For example, our subjects had baseline values that were 38% and 61% higher for 
the chest and leg press, respectively, than those of Galvao et al. (61), but when chest 
press 1RM was normalized to FFM, the strength levels between the two studies were 
identical. These baseline differences likely account for the percent change differences 
between the studies (19.5% vs. 40.5%), given that the absolute gains in 1RM were nearly 
identical when similar training periods were compared. However, normalization to FFM 
did not rectify the strength discrepancy on the leg press at baseline. Other studies of PCa 
patients on ADT report improvements of 41% and 32% in muscle fitness on the chest and 
leg press exercises during the standard load test (176) and isometric knee extensor 1RM 
gains of 20% and 7% for the right and left leg, respectively (74). Within the current 
study, the improvement in 1RM across the different tests were consistent, with only the 
left leg knee extensor 1RM lagging slightly behind. The left leg was typically the non-
dominant leg and patients reported greater and more frequent pain and discomfort in this 
limb during testing, both of which may explain the lower response. 
Overall, the PCa patients in the current study had baseline physical function levels 
similar to other PCa patients on ADT (35, 61, 64, 74, 125) and lower than healthy 
controls (63, 65, 76) and non-ADT PCa patients (74). All functional tasks were improved 
with training in the current study. The extent of the improvements was greater than some 
studies (64), while similar to (74) and less than others (61). Generally, these differences 
were minor and may be related to variations in training duration, types of training, and 
the number of sets per exercise. In addition, the average change in physical function 
across studies was smaller than what was observed for muscle power, strength, or 




the walking tests (117, 133).  In addition, there may be a ceiling effect on the fitness 
levels necessary to successfully perform some functional tasks, limiting improvements. 
Because our subjects were willing and able to drive themselves to our training facility for 
every testing and training session, their initial fitness level may have been beyond the 
threshold for optimal improvements via increasing fitness level. Similar situations have 
been discussed previously with respect to healthy, well-functioning older adults (63, 76). 
Still, there is abundant evidence available that supports the use of ST to maintain and 
improve physical function in men with PCa on ADT. 
 The significant decline in fatigue with ST that we observed corresponds with and 
may even exceed changes reported by others, though comparing disparate fatigue scales 
makes direct comparisons difficult (64, 176, 177). Although most ST interventions report 
improvements in fatigue perception (176, 177), the changes within the intervention group 
alone rarely meet the benchmark for clinical significance (30). Only when the scores 
from the control group are factored in are consistent differences in fatigue observed with 
ST. 
 The overall FACT-P scores indicating QoL in the current study are nearly 
identical to previous investigations (74, 176, 177). After ST, the overall FACT-P score 
was 7.5 units higher, which falls within the range for representing clinically meaningful 
changes (31). This improvement is slightly larger than one study (176) while another 
study reported no statistical change in ADT patients, despite an increase of 8.2 units (74), 
though this was likely due to sample size constraints. Other studies using different 
exercise and PCa populations also observed improved QoL in the intervention group 




indications of a trend between ST intensity and QoL changes, as studies using moderate 
intensity training (60-70% of 1RM) report smaller changes (176, 177) than those using 
higher intensities (70-85% of 1RM) (64), including the current study.   
  Our finding that improvements in physical function could be at least partially 
predicted from improvements in muscle function with training and length of ADT 
treatment provides some support for our initial hypothesis. While ST can improve 
physical function, fatigue perception, and QoL in PCa patients, the factors that contribute 
to these gains are less clear. Knowledge of the physiological traits that best predict 
improvement could aid in tailoring exercise prescription to target specific attributes. 
While we, and others, have previously attempted to predict gains in function in older 
adults (26, 32, 76), we are not aware of any studies attempting this in PCa patients, 
though one study did examine the correlations between changes in muscle function and 
general health (64). Our findings confirm a previous study in healthy older adults where 
changes in strength were associated with improvements in function (32) but this 
relationship is not always observed (26). The lack of a relationship between body 
composition and physical function alterations with ST was contrary to our hypothesis, 
based on our earlier findings in healthy older adults (76). Unfortunately, the lack of a 
discernable pattern as to which variable(s) best predict physical function somewhat 
diminishes the impact of these findings. 
 The ability to predict changes in fatigue perception was limited whereas FACT-P 
scores could be predicted to a greater extent, supporting the idea that improvements in 
physical function and fatigue levels influence QoL. We are aware of only one other study 




correlation between the changes in lean mass and general health, but the strength of this 
relationship was not reported. Thus, valid comparisons between their findings and the 
current study are not possible. Although the regression analyses were only exploratory, it 
does appear to provide preliminary support for the hypothesis that physiological 
improvements with ST is linked to improvements in fatigue and function, and ultimately 
to QoL. This information may be useful in generating new hypotheses for future studies. 
 Despite racial differences in incidence and mortality rates of PCa (2, 101) and in 
baseline muscle and fat mass (70, 207), we found no indication that black men on ADT 
respond differently to ST than other racial or ethnic groups reported previously (61, 64, 
74, 176, 177). Prior to the current study, there were no studies that compared racial 
influences on response to exercise training in PCa patients on ADT. Moreover, it was 
difficult to determine if black PCa patients were even included because information on 
the racial and ethnic backgrounds were not described (61, 64, 176, 177).  
 There were several limitations to this study. First, all subjects were volunteers and 
therefore may not reflect the typical PCa patient who chooses not to exercise as described 
in this study. Second, subjects were not randomized into exercise vs. no exercise groups. 
Difficulties in patient recruitment precluded recruitment of a separate non exercise 
control group. Although this may have prevented proper controls for methodological, 
biological, and seasonal variation, some of the variables, such as muscle mass, were not 
likely to be significantly influenced by these factors. In addition, any influences would 
likely be random and not systematic, making it unlikely to result in one direction of 
change. Also, subjects were familiarized twice with the ST equipment prior to 




Finally, while all PCa patients were on ADT, the use of other treatment types (radiation 
therapy and/or radical prostatectomy) and the length of ADT varied between subjects. 
Although length of ADT was not a significant factor in most cases, we were only able to 
examine the effects of chronic ADT treatment (>1 year). The effects of ADT tend to be 
most prominent in the first six to 12 months, thus future ST interventions should be 
initiated during this time period. 
Conclusion 
 Strength training is an effective intervention for counteracting the adverse 
musculoskeletal side effects of ADT in black PCa patients. The magnitude of 
improvements in muscle power, mass, and strength compare favorably to those 
improvements that occur in healthy black adults of similar age. The gains in muscle mass 
and power are particularly noteworthy, as they play key roles in maintaining functional 
independence and a high standard of living. Future studies should examine exercise 
intensities and training loads and the mechanisms responsible for gains in FFM in the 
















Specific Aims  







Specific Aims and Hypotheses 
Specific Aim #1: To determine whether ST can improve musculoskeletal health and 
regional and total body composition in black men undergoing ADT for treatment of PCa.  
Hypothesis #1: ST will induce significant gains in muscle strength, endurance, power, 
MV and total body FFM with no change in BMC, SCF, IMF, and total fat mass. 
Specific Aim #2: To compare the musculoskeletal health and body composition response 
to ST of PCa patients on ADT with a healthy black reference control population. 
Hypothesis #2: The absence of testosterone in PCa patients will blunt ST-induced gains 
in MV, strength, and power compared with a reference controls.  
Specific Aim #3: To determine whether ST can improve physical function, fatigue, and 
QoL and are these improvements associated with the changes in muscle function and 
body composition in black men undergoing ADT for treatment of PCa. 
Hypothesis #3a: ST will increase performance on simulated activities of daily living, 
decrease levels of generalized fatigue perception, and improve QoL. 
Hypothesis #3b: ST induced improvements in muscle volume, strength, endurance 
(fatigue resistance), power, and FFM will be associated with significantly improved 
performance on simulated activities of daily living, reduced levels of generalized fatigue 






1 RM: Refers to the maximal amount of resistance that an individual can successfully 
move throughout the complete range of motion only one time. 
5 RM: Refers to the maximal amount of resistance that an individual can successfully 
move throughout the complete range of motion only five times. 
Androgen Deprivation Therapy (ADT): The ablation of endogenous sources of 
testosterone as an adjuvant treatment of PCa. In this study, ADT was accomplished 
through the use of Luteinizing Hormone Releasing Hormone agonists and/or anti-
androgen treatments that block testosterone from binding to the androgen receptor.  
Appendicular Fat Free Mass: The sum of the lean tissue of the arms and legs, as 
determined by DEXA. 
Brief Fatigue Inventory (BFI): A questionnaire used to quantify generalized fatigue 
perception and to distinguish it from localized muscle fatigue.    
Computed tomography (CT): A technique for assessing regional muscle mass based on 
analysis of axial scans of the thigh. Visual images are created from the measurement of 
the intensity of x-rays and are analyzed to measure the cross-sectional area. The images 
are based on the attenuation of x-rays as they pass through the body. Attenuation scores 
are measured in Hounsfield units, which depend upon the level of absorption of emitted 
x-ray beams, -1000 in air to +1000 in bone. Skeletal muscle typically ranges from 0 to 
100 Hounsfield units while adipose tissue is usually -190 to -30 Hounsfield units. 
Dual-energy x-ray absorptiometry (DEXA): A technique used for assessing whole and 




compartments: bone mineral mass, soft tissue, and lean tissue. Tissue quantities are based 
on the attenuation of x-rays as they pass through the body. 
Fatigue resistance: An increased number of successful repetitions on the muscle 
endurance repetition test. 
Functional Assessment of Cancer Therapy-Prostate (FACT-P): A questionnaire that 
is a relevant, worldwide tool used for assessing the health-related quality of life in men 
with PCa. It is composed of physical, social, emotional, and functional well-being 
sections, along with a section of concerns specific to PCa. 
Localized Muscle Fatigue: The number of repetitions achieved throughout the full range 
of motion without pausing during the chest press and leg press when performed at 70% of 
baseline (pre training) 1RM.     
Muscle volume (MV): Muscle volume with be determined from the cross-sectional axial 
CT scans using the MIPAV software and the equations of Tracy et al. (197). Briefly, this 
process entails an equation that utilizes the 8-10 thigh slices of each thigh to create an 
estimate for muscle volume. 
Sarcopenia: A condition characterized by the loss of muscle size, quality, and function 
that occurs with aging. This typically leads to or exacerbates ailments such as 
osteoporosis and loss of functional independence. 
Prostate Cancer (PCa): All physician diagnosed malignant tumors of the prostate gland, 
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Appendix II: Forms 
Maryland CARES 
Initial Screening Form 
 









Home Phone number: _______________________________________________ 
 
Work Phone number: ________________________________________________ 
 




Preferred method and time to reach you: _________________________________ 
 
2. AGE and DATE OF BIRTH: 
 
3. CURRENT HEIGHT and WEIGHT: 
 
4. WOULD YOU CLASSIFY YOURSELF AS BLACK: YES / NO 
 
5. PROXIMITY TO UMD COLLEGE PARK CAMPUS: 
-Distance from campus: 
 
-Willingness to travel to UMD campus 3 times per week for 12 weeks:  YES / NO 
 
-Times available for training AM_______ PM_________ Other______________ 
 
6. MEDICAL HISTORY: 
-Have you been diagnosed by a physician as having prostate cancer? YES / NO 
  





-Current Androgen Deprivation Therapy medications you are taking: 
 
       GnRH Antagonists    GnRH Agonists 
1. Abarelix (Plenaxis)    1.   Leuprolide (Lupron, Eligard) 
2. Histrelin (Supprelin-LA)   2.   Buserelin (Suprefact) 
3. Cetrorelix (Cetrotide)    3.   Nafarelin (Synarel) 
4. Ganirelix (Antagon)    4.   Histrelin (Supprelin) 
      5.   Other-please specify    5.   Goserelin (Zoladex) 
       6.   Deslorelin  
       7.   Triptorelin 
       8.   Other- please specify 
 
-What is your current Prostrate-Specific Antigen (PSA) value? 
 
-Do you have any medical conditions (other than PCa), surgeries or any other condition 
that you feel may prevent you from exercising vigorously? YES   /    NO       If YES, 
please describe these conditions: 
 
 
7.   MEDICAL CONDITIONS: 
-Please indicate YES / NO / DON’T KNOW if you currently have any of the medical 
conditions: 
 
______Severe cardiovascular disease, such as: 
______unstable angina 
______uncontrollable hypertension (high blood pressure) 
______uncontrolled dysrhythmias (irregular heart rate) 
______severe stenotic or regurgitant valvular disease 
______hypertrophic cardiomyopathy 
______symptomatic peripheral arterial disease 
______Severe COPD or other signs of significant pulmonary dysfunction 
______Intracranial aneurysm 
______Previous stroke 
______Musculoskeletal diseases that cause severe joint pain at rest or upon exertion 
______Diseases that promote muscle protein breakdown 
______Joint, vascular, abdominal or thoracic surgery in the past year 
______History of bone fragility fractures 
______Having any condition that is likely to be aggravated by muscular exertion 
______Being unable to engage safely in mild to moderate exercise, such as 
independently walking up at least one flight of stairs or walking two blocks on 
level ground 
______Diabetes 







8.   CORONARY ARTERY DISEASE RISK FACTORS 
- Please indicate YES / NO / DON’T KNOW for the Coronary Artery Disease Risk  
A. Family History as defined by: 
 ______Myocardial infarction (Heart attack) 
 ______Coronary revascularization 
 ______Sudden death before 55 years of age in father or other male first   
 degree relative                   
______Sudden death before 65 years of age in mother or other female first  
 degree relative 
 
B. Cigarette smoker as defined by: 
 ______Current smoker 
 ______Quit within the previous 6 months 
 
C. Hypertension (High Blood pressure) as defined by: 
 ______Systolic blood pressure ≥ 140 mm Hg or Diastolic blood pressure ≥ 
 100mm Hg  confirmed by measurements on at least 2 separate 
 occasions. 
 ______On antihypertensive medications. 
 
D. Dyslipidemia (High Cholesterol) as defined by: 
 ______Total cholesterol ≥ 200 mg/dl  
 ______High density lipoprotein (HDL) cholesterol < 40 mg/dl 
 ______Low density lipoprotein (LDL) cholesterol ≥ 130 mg/dl 
 ______On lipid lowering medications 
 
E. Diabetes (High Blood Sugar) 
 ______Fasting Blood Glucose ≥ 126 mg/dl confirmed by measurements on 2  
 separate occasions 
 
F. Obesity as defined by: 
 ______Body Mass Index (BMI) ≥ 30 kg/m2 
 ______Waist Girth ≥ 102 cm for men 
 ______Waist hip ratio ≥ 0.95 
 
9.   CURRENT PHYSICAL ACTIVITY LEVEL: 
- Do you participate in any type of regular physical activity or exercise? YES / NO 
 If YES, please describe what types of exercise you do: 
 How many days per week do you exercise?  ______ 
 How long does each exercise session typically last?  ______ 
  How difficult (on a scale of 1-10) is each session?  ______ 




Medical Clearance to Participate in Research Project 
 
It is my understanding that _________________________ (name of the volunteer), a patient 
under my care, has volunteered to participate in the study entitled, “ Strength Training to 
Improve Muscle Function, Quality of Life, and Self Efficacy in Patients with Prostate 
Cancer.” The volunteer must have the approval of his physician to participate in this study.  
Please record date and results of last exercise stress test, if known.  
______________________________________________________________  
 
Exclusionary criteria for eligibility are listed below. If you believe that your patient named above 
has any of the medical conditions indicated below, please place a check in front of the 
condition(s) indicated: 
 
____ Severe cardiovascular disease, such as ____unstable angina, ____uncontrollable  
hypertension, ____uncontrolled dysrhythmias, ____severe stenotic or regurgitant 
valvular disease, ____hypertrophic cardiomyopathy, and ____symptomatic peripheral 
arterial disease 
____ Severe COPD or other signs of significant pulmonary dysfunction 
____ Intracranial aneurysm 
____ Previous stroke 
____ Musculoskeletal diseases that cause severe joint pain at rest or upon exertion 
____ Diseases that promote muscle protein breakdown 
____ Joint, vascular, abdominal or thoracic surgery in the past year 
____ History of bone fragility fractures 
____ Having any condition that is likely to be aggravated by muscular exertion 
____ Being unable to engage safely in mild to moderate exercise, such as independently walking 
up at least one flight of stairs or walking two blocks on level ground 
 
There is evidence of non-fatal subarachnoid hemorrhage in patients with pre-existing intracranial 
aneurysms and aortic dissection in predisposed patients, associated with strength training. For this 
reason, any patient who has known, suspected, or at high risk for intracranial aneurysms, aortic 
dissection, connective tissue disease or uncontrolled hypertension should not participate in this 
study. 
 
Please check one of the following: 
____ Clearance granted 
____ Clearance not granted 
____ Send me the following information about the study 
 
Volunteers in this study will participate in resistance exercise under the supervision of exercise 
specialists under the direction of the Principal Investigator, Ben Hurley Ph.D., Professor, 
Department of Kinesiology, College of Health and Human Performance, University of Maryland, 
College Park, Maryland 20742 (email: benhur@umail.umd.edu; tele: 301-405-2486).  Please fax 
signed form: (301) 405-5578.   
 






Dept. of Kinesiology 
School of Public Health 





Re: Prostate Cancer History 
4 November 2009 
Dear Mr. 
 
Thank you for your interest in our research study. In order to continue the screening process, we 
need to confirm information from you about your prostate cancer history. Please fill out the form 
below, being as specific as possible. If you do not know the answers to these questions, we ask 
that you speak with your urologist or oncologist to help obtain this information. Please bring the 
completed form with you to your orientation session. Thank you for your cooperation. If you 
have any questions, please feel free to contact us. We look forward to working with you. 
 
1. Prostate Cancer Diagnosis Date (exact date): 
_____________________________________________________________________ 
 
2. Androgen deprivation therapy (ADT) start date (exact date): 
_____________________________________________________________________ 
 




 Frequency of ADT injections: ______________________________________ 
 
 Will you remain on ADT medication for the next 3-4 months? ____ Yes ____ No 
 
4. Once you started ADT therapy, have you been on it continuously? ____ Yes ____ No 
 




5. Radiation therapy start date and number of sessions (if applicable): ____________ 
 
6. Have you ever had a prostatectomy? _____ Yes _____ No 
 
 Date of surgery: ____________________ 
 




Detailed Medical History for the Maryland CARES Study 
 
Name:_____________________________ Date:______________  
Name of Interviewer: ___________________________ 
Emergency contact:___________________________________________________ 
____________________________________________________________________ 
Have you ever been a patient at Washington Adventist Hospital?_____________ 
DIRECTIONS: 
Read the following questions out loud to each prospective volunteer and check “yes” or 
“no”. Any answers that require qualification should be written in the space below the 





Have you ever been told by your doctor that you have any of the following? 
 
a. Osteoarthritis or degenerative arthritis    ____ ____ 
b. Rheumatoid arthritis       ____ ____ 
c. Unknown or other type of arthritis     ____ ____ 
d. Osteoporosis        ____ ____ 
e.   Any other disease of joint or muscle:     ____ ____ 
Comments:         ______




1. Has any family member had a heart attack prior to the age of 55?  ____ ____   
If so, please describe the relationship:    
2. Have you ever had frequent cramping in your legs?   ____ ____ 
If yes, is it a current problem?     ____ ____ 
3. Have you ever had pain or cramping in your legs while walking? ____ ____ 
If yes, is it a current problem?     ____ ____ 





4. Have you ever been told that you have high blood pressure?  ____  ____ 
                  If yes,     
a. What was the date of diagnosis? _________________  
b. Were you given any medications?    ____ ____ 
(Please list the medications with dose on the last page) 
c. How long have you been on the medications? ________________ 
d. Has there been a recent change in the medications and if so, when? 
_________________________________________________________         
5. Did a doctor ever tell you that you had a heart problem?   ____ ____ 
            If yes, 
a. What was the date of onset?__________________________________ 
b. What did the doctor call it? (eg: Angina, Heart Failure, Heart Attack,  
  Rhythm disturbances, heart murmurs, enlarged heart, diseases of heart 
valves, others). Please circle relevant one(s). If others, please ask subject to 
explain. 
 
c. Were you given any medications?  (Please list the medications with dose on 
the last page) 
 
d. Was Echocardiography ever done?    ____ ____  
6.   Have you ever had any chest pain due to a respiratory or digestive problem?                                               
          ____ ____ 
If yes, 
a. Month and year of the first occurrence? _____________ 
b. Month and year of the most recent occurrence? _____________ 
c. What was the frequency of occurrence? (eg: once a month, once a week, 






d. How would you describe the pain or discomfort? (Eg: Pressure, Burning, 
Squeezing, Piercing, Stabbing, Shooting or Sticking) Circle appropriate 
one or if different, please describe: 
e.  
  How many minutes did it last?_____________ 
f. Does the pain or discomfort move? If yes, to where?                              
g. Does the pain or discomfort tend to occur:  
           After meals?      ____ ____ 
           At night?       ____ ____ 
           When Exercising?     ____ ____ 
 When walking in cold windy weather?   ____ ____ 
           When upset, excited or nervous?    ____ ____ 
Other?  
h. Is this pain relieved by 
     A change in posture?     ____ ____
 Rest?       ____ ____ 
           Physical activity?      ____ ____ 
 Bicarbonate of soda, Tums or antacids?   ____ ____ 
            Prescribed medications?     ____ ____ 
 Other? 
i. Did you ever consult a doctor for this pain or discomfort? ____ ____ 
              If yes, 
              Do you know the diagnosis?______________________________ 
Were you given any medications and if so was there a recent change 






7. Do you have any history of high cholesterol in your blood as evident by  
          previous blood tests?      ____ ____ 
Comments:           




1. Have you ever had persistent cough with sputum production for almost all days         
      for 3 months?        ____ ____ 
            If yes, 
a. How long did it last? 
b. Did your doctor prescribe any medications and has there been any recent 
change in the medications?  (Please list on last page, if any) 
 
2. Have you ever had attacks of wheezing?    ____ ____ 
           If yes, 
a. Was it seasonal/ periodic?     ____ ____ 
b.  Have you ever-required hospitalization to abort an acute attack? 
____ ____ 
Comments:           




Has your doctor ever told you that you have any of the following problems? 
a. Thyroid problems?      ____ ____ 
b. Adrenal problems?      ____ ____ 
c.  Diabetes mellitus?       ____ ____ 
       If yes, which type?      
                   Date of onset-____________ 







1.Do you have any problems with your memory?    ____ ____ 
If yes,  
a. When answering the telephone, do you recall what you were doing before it 
rang?        ____ ____  
b. If someone calls you, can you give the directions to your house? 
        ____ ____ 
c. Can you keep appointments without a reminder?  ____ ____ 
d. Can you remember what clothes you wore yesterday?  ____ ____ 
If the subject answers “no” to any of the above questions 
Do a Mini Mental Status Examination of the subject.  
    2.   Any problems with vision other than corrective lens changes? ____ ____ 
      If yes, which of the following conditions- Blindness, Temporary loss    
      of vision, Double vision, Glaucoma, Cataract, Macular degeneration 
       or others. 
 
    3.  Ringing in your ears?       ____ ____ 
4. Vertigo (a feeling of spinning, or unsteadiness)?   ____ ____ 
5. Fainting Spells (black outs)?      ____ ____ 
6. Seizure or convulsions?      ____ ____ 
7. Migraine or severe headaches?      ____ ____ 
8. Paralysis of arm or leg?      ____ ____ 
9. A head injury with loss of consciousness?    ____ ____ 
10. Pain, numbness or tingling in your arm or hand?   ____ ____ 
11. Pain in your lower back?      ____ ____ 





13. Ruptured vertebral disc in neck or back?    ____ ____ 
14. Have you had pain in any part of body (including headache) while exercising? 
          ____ ____  
15.  Numbness or pain in your legs?     ____ ____ 
16. Have you been told that you have a peripheral neuropathy?  ____ ____ 
17. Tremors?        ____ ____ 
18. Problems with walking?      ____ ____ 
a. Do you fall frequently      ____ ____ 
b. Is your walking problem related to pain, weakness or loss of balance? 
         ____ ____ 
19. Stroke         ____ ____ 
20. Epilepsy        ____ ____ 
21. Operations on skull or brain?      ____ ____ 
22. Multiple sclerosis?       ____ ____ 
23. Meningitis or Brain fever?      ____ ____ 
24. Parkinson’s disease?       ____ ____ 
25. Any history of neurological consultation?    ____ ____ 
Comments:           
            
SECTION F                        
Hematology/Immunology/Oncology: 
 
1. Have you ever been told by your physician that you had a problem with 
        anemia or any disease of the red blood cells or the white blood cells? 
          ____ ____ 





      3.    Do you have any history of bleeding disorder?   ____ ____  
4.    Have you ever been diagnosed as having any type of cancer ____ ____ 
 other than PCa? 
      If yes, which organ, date of onset?______________________________________ 
6. Were you given any medications, radiation or undergone any surgery? 
____ ____ 
Comments:           
            
 
SECTION G          
PCa History: 
 
1. When were you first diagnosed with PCa? 
 
2. When did you first start taking androgen deprivation therapy? 
 
3. Which ADT medication(s) are you currently taking? 
 
4. Have you had a stable PSA of <2ng/ml for 3 months?  ____ ____ 
 
5. Have you ever had a prostatectomy?     ____ ____ 
If so, when? 
 
6. Have you undergone radiation therapy?    ____ ____ 
If so, when and how many sessions? 
 
7. What is your Gleason score (2-10)? 
 
8. What is the stage of your cancer progression? 
 
SECTION H          
Surgical History: 
 
1. Have you undergone any surgeries? (Please include abdominal surgery).  
         ____ ____ 
If yes,   
a. Where and for what purpose? ___________________ 
b. Date of Surgery? _____________________________ 





d. Any complications of Surgery? _________________ 
2. Has a doctor ever told that you have been suffering from  
a) Cystic medial degeneration?     ____ ____ 
 
b) Any Connective tissue disorder?     ____ ____ 
 
3. Have any of your family members had an intracranial aneurysm or bleeding? 
____ ____ 
  
4. Have you ever been diagnosed with an abdominal aneurysm? ____ ____ 
 
5. History of severe pain in the abdomen  
 ____ ____ 
      If yes, Please specify_______________________________ 
 
6. Any history of severe headache? ____ ____ 
If Yes, what was the date of onset?_________________ 
 
7. Was it associated with neurological signs like blurred vision, nausea/vomiting, 
seizures, drowsiness, memory impairment, sensory or motor loss( weakness)? 
  
 ____ ____ 
 
8. Was it a new or different type of headache other than tension, migraine etc? 
  
 ____ ____  
 
9. Was it the worst ever experienced  
 ____ ____ 
 
10. Did it occur after exertion, coughing or straining? ____    ____ 
 
Comments:          





1. Do you exercise regularly?      ____    ____ 
If yes, 
a. Do you perform aerobic exercise, strength training, both, or another form of 
exercise? 
 
b. How often do you exercise per week? 
 




c. How long are your training sessions? 
 
d. How challenging would you say your training sessions are on a scale of 1-10, 
with 1 being easy and 10 being extremely challenging? 
 
2. Do you smoke regularly?      ____   ____ 
If yes, 
a. How long have you been smoking? 
 
b. How many packs per day? 
 
If no, 
a. Have you ever smoked in the past?    ____   ____ 
 
b. How long ago did you quit smoking? 
 
c. How long did you smoke for? 
 
3. How many alcoholic beverages do you consume per week (on average)? 
_____None 
_____Less than 3 per week 
_____3 to 5 per week 
_____6 to 8 per week 
_____9 to 11 per week 
_____12 to 14 per week 
_____More than 14 per week 
 
4. Do you consume a particular diet?     ____   ____ 
If yes, please describe. 
 
5. Do you avoid high fat foods?      ____   ____ 
 
6. Do you avoid high carbohydrate foods?    ____   ____ 
 
7. Are there any food groups or types that you avoid?   ____   ____ 
If so, which ones? 
 
8. How many servings of fruits and vegetables do you consume per day? 
_____Less than 2 servings per day 
_____2 to 4 servings per day 
_____5 to 9 servings per day 
_____More than 9 servings per day 
 
9. Do you consume any dietary supplements?    ____   ____ 









1. Do you have children?      ____ ____ 
If so, how many? 
 
2. Have you ever been married?      ____ ____ 
 
3. Are you currently married?      ____ ____ 
 
4. What is the highest level of education that you completed? 
_____Some high school 
_____High school graduate or equivalent 
_____Vocational/Training school after High School 
_____Some College (no degree) 
_____Associates Degree 
_____College Graduate 
_____Some Graduate or Professional School after College Graduation 
_____Complete Graduate/Professional School 
 
5. Are you currently employed?      ____ ____ 
If no, 
a. Are you retired?      ____ ____ 
If yes, what is your approximate income level? 






_____$100,000 or more 
 




7. How many hours per week do work on average? 
_____Less than 10 hours per week 
_____10 to 20 hours per week 
_____20 to 30 hours per week 
_____30 to 40 hours per week 
_____40 to 50 hours per week 
_____50 hours per week or more 
 













If yes, please specify_______________________________________________ 
________________________________________________________________ 
2. Are you currently on any other medications not covered previously? 
____ ____ 
3. How did you hear about this study? 
Comments:           

























Consent to Participate in a Research Study 
 
Project Title: Strength training to improve muscle function, quality of life, and self 
efficacy in patients with prostate cancer 
 
Why is this research being done? This is a research project being conducted by Drs. 
Ben Hurley and Stephen Roth at the University of Maryland, College Park.  We are 
inviting you to participate in this study designed to determine the effectiveness of regular 
resistance type exercise (strength training). We will test the effects of strength training on 
muscle mass, muscle function, body composition, quality of life, performance of 
common physical tasks and desire to continue to exercise regularly in men with prostate 
cancer who are taking androgen deprivation therapy. We are seeking this information to 
determine if strength training can serve as an appropriate adjunct therapy for prostate 
cancer patients who are on androgen deprivation therapy.  
 
What will I be asked to do? The study will take place in the Department of Kinesiology 
at the University of Maryland in College Park and the procedures will involve three 
phases.  During the first phase, you will undergo baseline testing, which will include a 
blood draw to analyze blood proteins and DNA (genetic material) related to prostate 
cancer, assessments of blood pressure, body composition, bone mineral density, leg 
muscle mass, fat surrounding leg muscles, muscle strength, muscle power, muscle 
fatigue, quality of life, desire to exercise regularly, and ability to complete selected tasks 
designed to mimic common physical activities of daily living. This first phase of baseline 
testing will require approximately 4 hours. The second phase of the study involves your 
participation in a strength training program three times a week for approximately six 
months. The strength training program will involve training all the major muscle groups 
(full body training) for approximately 12 weeks. Each training session will require 
approximately 30 minutes, with an additional 10 minutes required for blood pressure 
measurements, warm-up and stretching at each session. The third and final phase will be 
a repeat of all baseline testing. Leg muscle mass, fat surrounding leg muscles, muscle 
strength, muscle power and muscle fatigue assessments will be repeated after the training 
program.  The blood draw will require providing approximately 2 to 3 tablespoons of 
blood at baseline and this amount will be required again after the training program, for a 
total of 4 to 6 tablespoons of blood.  This blood will be separated and stored at the 
University of Maryland for later analysis of blood proteins thought to be important for 
prostate cancer.  A portion of this sample may also be used for potential future studies, 
but only as such studies apply to a better understanding of exercise and prostate cancer.  
However, you may contact the principal investigator at any future point in time to request 
that any stored blood sample be destroyed immediately.  Another portion of the blood 
sample will also be used for extracting your DNA to assess the variation of some of your 
genes related to prostate cancer risk.  This information will be used only to determine if 
specific DNA variants influence your response to the exercise training program. It will 
not be used for diagnostic, prognostic, or treatment purposes. You will be asked to make 
your DNA sample available for future studies, but only for a period of no longer than 10 





Initial_____  Date__________ Page 2 of 5 
Project Title:  Strength training to improve muscle function, quality of life, and self 
efficacy in patients with prostate cancer 
 
the purpose of identifying new genes and gene sequence variants that relate to exercise 
and prostate cancer.  Because this part of the study is exploratory, we will not provide 
your genetic information to you.  If you choose not to provide a DNA sample, it will not 
make you ineligible to participate in the study. 
 While you are lying on a padded table, your leg muscle and fat mass will be 
measured by computed tomography (CT). The CT scan will be performed at Washington 
Adventist Hospital. Your percent body fat and bone mineral density measurements will 
be performed at the United States Department of Agriculture in Beltsville, Maryland by 
dual-energy x-ray absorptiometry (DXA). This will require lying still on a padded exam 
table wearing metal-free clothing for about 10 minutes at a time, totaling less than 30 
minutes for the entire procedure for each test. The DXA and CT testing will be performed 
before and after both strength training program.   
Muscle strength, power and fatigue assessments will be performed on machines that 
measure how much force, how fast, and how long you can continue to exert force through 
a typical range of knee extension motion. Strength testing will also be performed by 
measuring the maximal force that you can move through the full range of an exercise on 
the same machine. During each strength training session you will be asked to exercise on 
machines that offer resistance against extending and flexing your legs, arms, and trunk 
region three times a week for up to 4 months.  You will be asked to complete some tasks 
to measure your ability to carry out normal daily activities. These tasks include rising 
from a chair, short brisk walks and climbing stairs. You will be asked to fill out 
questionnaires before and after the strength training programs, which present questions 
related to your perception of fatigue, health related quality of life, and attitude toward 
participating in strength training exercises on a regular basis.  The questions will ask you 
to identify specific feelings and consequences elicited from your fatigue and your overall 
well being. Questions will also deal with your concerns specific to prostate cancer and its 
treatment, as well as your attitude concerning adopting strength training as a life style 
habit (self-efficacy). Additional questions will be administered to determine whether self-
efficacy is related to quality of life indicators or side effects from medications.   
If you are taking other medications in addition to androgen deprivation therapy prior 
to the study, you will be permitted to participate as long as you have been on these 
mediations for at least 4 weeks prior to the study and do not stop taking them prior to the 
end of the study.  
To be eligible to participate, your physician must sign a medical clearance form.  It is 
possible that you could go through baseline evaluations and be determined to be 
ineligible to participate. Upon completing all aspects of the study, you will also receive 
$300 for your participation.   
 
What are the risks of this research?  There is a risk of bruising, pain and, in rare cases, 
infection or fainting as a result of blood sampling. However, these risks will be 
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and bone density testing completed by CT and DXA involves radiation exposure, which 
increases the risk of passing genetic mutations to offspring, but this risk is a concern 
primarily among women of childbearing age. There will be a total radiation dose of no 
more than 1 Rem (1000 millirems) to the whole body from each CT scan. This amount is 
well below the maximal annual radiation dose (5000 millirems) allowed for exposure in 
the workplace. The radiation exposure from DXA is equal to an exposure of less than 50 
millirems to the whole body.  Naturally occurring radiation (cosmic radiation, radon, etc.) 
produces whole body radiation of about 300 millirems per year. Therefore, the total dose 
of radiation exposure due to the combined dose of DXA and CT is considered low. 
However, x-ray exposure is cumulative and there is no known lower limit below which x-
ray exposure is known to be safe for men or women. You may experience some 
temporary muscle fatigue and soreness as a result of the testing sessions. 
There is also a risk of muscle or skeletal injury from strength, power, and fatigue 
testing, as well as from strength training. The investigators of this study will use 
procedures designed to minimize this risk. It is also possible that heart or blood vessel 
problems could arise during your participation in the testing or training involved in this 
study. Although unusual, it is even possible that these problems could lead to a heart 
attack or stroke. For this reason, prior medical evaluation and clearance from your 
physician at your expense will be required to participate in this study. It is possible that 
these risks will not be eliminated completely, even with a medical evaluation prior to 
participation in the study. There is a risk of injury from falling, but any risk of injury 
during the completion of these tasks will be minimized by having all sessions supervised 
by an exercise physiologist qualified to direct this type of testing. Also, we will require 
those who are at risk of falling, based on their walking ability and performance on other 
functional tests, to wear a safety harness during the short brisk walks and climbing a 
flight of stairs. 
 
What are the benefits of this research? This study is not designed to help you 
personally, but rather to help the investigators of this study and eventually to society in 
general to better understand the utility of using strength training as an adjunct therapy for 
prostate cancer patients who are taking androgen deprivation therapy. However, previous 
research has demonstrated that you will likely benefit in many ways as a result of your 
participation in the strength training program. This includes, but is not limited to, 
improvements in strength, muscle tone, resistance to fatigue, body composition, resting 
metabolic rate, muscle function, gastrointestinal transit, and sugar (glucose) metabolism. 
For your participation in the study, after completing the study, you will receive your 
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Do I have to be in this research? Your decision to participate in this study is voluntary 
and you are free to ask any questions about this study before you decide whether or not to 
participate.  
 
May I stop participating at any time? If you consent to participate, you are free to 
withdraw from participation at any time without penalty or coercion, or without any 
requirement to provide an explanation to anyone about your decision to withdraw. In 
addition, your refusal to participate will not involve a penalty or loss of benefit to which a 
volunteer would otherwise qualify. 
  
What about confidentiality? We will do our best to keep your personal information 
confidential. To help protect your confidentiality, we will keep your confidential records 
in secure and private storage areas, use password protected computer files for all 
collected data, and use identification codes instead of your name on data files, whenever 
possible. If we write a report or article about this research project, your identity will be 
protected to the maximum extent possible. Your information may be shared with 
representatives of the University of Maryland, College Park or governmental authorities 
if you or someone else is in danger or if we are required to do so by law.   
 
Is any medical treatment available if I am injured? The University of Maryland does 
not provide any medical, hospitalization or other insurance for participants in this 
research study, nor will the University of Maryland provide any medical treatment or 
compensation for any injury sustained as a result of participation in this research study, 
except as required by law.  
 
What if I volunteer as a control? A subgroup of volunteers will serve as a no exercise 
control group. If you are identified as a control for this study, you will undergo the 
identical testing as the other volunteers in the study and repeat testing at approximately 
the same time points as those who will participate in the strength training program, but 
you will not participate in any part of the strength training program. However, as 
compensation for your time for undergoing the testing procedures, controls will be 
permitted to have 6 weeks of supervised use of our exercise machines after all testing is 
complete, but will receive no financial compensation.   
 
What if I have questions? This research is being conducted by Drs. Ben Hurley and 
Stephen Roth in the Department of Kinesiology at the University of Maryland, College 
Park.  If you have any questions about the research study itself, please contact Dr. Ben 
Hurley at 301-405-2486. If you have questions about your rights as a research subject or 
wish to report a research-related injury, please contact: Institutional Review Board 
Office, University of Maryland, College Park, Maryland, 20742; (e-mail) 
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research has been reviewed according to the University of Maryland, College Park IRB 
procedures for research involving human subjects.  
 
Statement of Age of Subject and Consent. Your signature indicates that you are at least 
18 years of age, the research has been explained to you, your questions have been fully 
answered, and you freely and voluntarily choose to participate in this research project. 
 
Principal investigator: Ben Hurley, Ph.D., Dept of Kinesiology, HLHP Building, 
University of Maryland, College Park, MD 20742-2611, Ph: (301) 405-2486. 
 
 
Printed Name of Subject___________________________ 
 
 






CONSENT TO PARTICIPATE IN A RESEARCH PROJECT 
 
Project Title: Effects of Gene Variations on Age- and Strength Training-Induced 
Changes in Muscular Strength, Body Composition, Blood Pressure, Glucose Metabolism, 
and Lipoprotein lipid Profiles 
 
I state that I am over 18 years of age, in good physical health, and have elected to 
participate in a program of research being conducted by Dr. Ben Hurley in the 
Department of Kinesiology at the University of Maryland, College Park, MD 20742. 
I understand that the primary purpose of this study is to assess the role that 
genetics may play in causing losses of muscular strength and muscle mass with age and 
gains in strength and muscle mass as a result of strength training. I understand that 
another purpose of the study will be to assess the influence of genes on changes in body 
composition, blood pressure, blood sugar metabolism, blood fats muscle power, and 
performance of common physical tasks with age and strength training. 
I understand that the procedures involve three phases. During the first phase, I 
will undergo testing, which will include a blood draw to analyze my DNA (genetic 
material), blood sugar and fats, and other blood proteins. My blood pressure, body 
composition, bone mineral density, leg muscle volume, muscle strength, muscle power, 
and ability to complete selected tasks similar to common activities of daily living will 
also be assessed during this first phase. The second phase of the study involves my 
participation in a strength training program three times a week for approximately six 
months. The third and final phase will be a repeat of all previously taken measures, 
except analysis of my DNA, which will not need to be repeated. Some of the tests will be 
repeated both after~ 10 weeks of training and again after the entire training program. 
These repeat tests will include blood pressure, strength, power, muscle volume and body 
composition. Other tests will be repeated only after the entire training program. 
I understand that the blood draw will require providing about 2 to 3 tablespoons 
of blood. I understand that there is a risk of bruising, pain and, in rare cases, infection or 
fainting as a result of blood sampling. However, these risks to me will be minimized by 
allowing only qualified people to draw my blood. A portion of this blood sample will be 
sent to the University of Pittsburgh to analyze my DNA. I understand that the remainder 
will be stored at the University of Maryland for later analysis of my blood sugar, the 
hormone that regulates my blood sugar (insulin), blood fats, and other blood proteins. I 
understand that a portion of this sample may also be used for potential future studies, but 
only as such studies examine strength, body composition (i.e., fat, muscle & bone), 
metabolism of blood sugar, and blood pressure. I understand that I may contact the 
principal investigator at any future point in time to request that any stored blood sample 
be destroyed immediately.  
I understand that while I am lying on a padded table, my leg muscle and fat mass 
will be measured by computed tomography (CT). The CT scan will be performed at 
Washington Adventist Hospital. My percent body fat and bone mineral density 
measurements will be performed at the United States Department of Agriculture in 
Beltsville, Maryland by dual-energy x-ray absorptiometry (DXA). This will require my 
lying still on a padded exam table wearing metal-free clothing for about 10 minutes at a 




I understand that there will be a total radiation dose of no more than 1 Rem to the 
whole body (effective dose equivalent) from each CT scan. This amount is well below 
the maximal annual radiation dose (5 Rems) allowed for exposure in the workplace. The 
body composition and bone density testing completed by DXA involves a small radiation 
exposure. The radiation exposure I will receive from DXA is equal t to an exposure of 
less than 50 millirems to the whole body. Naturally occurring radiation (cosmic radiation, 
radon, etc.) produces whole body radiation of about 300 millirems per year. Therefore, 
the total dose of radiation exposure due to the DXA measurement is minimal and the 
combined dose of DXA and CT is considered low.  
I understand that strength and power assessments will be performed on machines 
that measure how much force and how fast I can exert force through a typical range of 
knee extension motion. Strength testing will also be performed on the same exercise 
machines used for training by measuring the maximal amount of force that I can move 
through the full range of an exercise. During each strength training session I will be asked 
to exercise on machines which offer resistance against extending and flexing my arms, 
legs, and trunk region for approximately 40 minutes or less a day, three times a week for 
up to six months. I understand that I may experience some temporary muscle soreness as 
a result of the testing sessions. There is also a risk of muscle or skeletal injury from 
strength and power testing, as well as from strength training. The investigators of this 
study will use procedures designed to minimize this risk.  
I understand that I will be asked to complete some tasks to measure my ability to 
carry out normal daily activities. These tasks include rising from a chair, short brisk 
walks and climbing a flight of stairs. Any risk of injury during the completion of these 
tasks will be minimized by having all sessions supervised by an exercise physiologist 
qualified to direct this type of testing and wearing a safety harness during the short brisk 
walks and climbing a flight of stairs. 
I understand that it is also possible that heart or blood vessel problems could arise 
during my participation in the testing or training involved in this study. Although 
unusual, it is possible that these problems could lead to a heart attack or even death. 
Therefore, prior evaluation and permission from my physician at my expense will be 
required to participate in this study. I also understand that it is possible that these risks 
will not be eliminated completely, even with a medical evaluation prior to participation in 
the study. 
I understand that this study is not designed to help me personally, but may help 
the investigators better understand who is likely to be most and least susceptible to losing 
strength, power, and muscle mass with advanced age and who is most and least likely to 
benefit from strength training. 
I understand that my decision of whether or not to participate in this study is 
voluntary. I understand that I am free to ask questions about this study before I decide 
whether or not to participate in the study. I understand that if I consent to participate in 
the study I am free to withdraw from participation at any time without penalty or 
coercion, or without any requirement that I provide an explanation to anyone of my 
decision to withdraw. In addition,  
I understand that refusal to participate will not involve a penalty or loss of benefit 
to which a volunteer would ordinarily be entitled to at that time. If I am on hormone 




HRT prior to the study, I must remain off them throughout the study to qualify for 
continued participation. If I am taking other medications prior to the study, I will be 
permitted to participate as long as I had been on these mediations for at least 4 weeks 
prior to the study and do not stop taking them prior to the end of the study. I understand 
that all information collected in this study is confidential. For my participation in the 
study I will receive information after the study is completed about my blood pressure, 
blood test results, bone mineral density, body composition, and functional ability upon 
request, free of charge. However, I understand that I will not receive any financial 
compensation in exchange for my participation in this study. 
In the event of physical injury resulting from participation in this study, upon my 
consent, emergency treatment will be available at the medical center of Washington 
Adventist Hospital with the understanding that any injury that requires medical attention 
becomes my financial responsibility. I understand that the University of Maryland at 
College Park will not provide any medical or hospitalization insurance coverage for 
participants in this research study, nor will they provide compensation for any injury 
sustained as a result of this research study, except as required by law. 
 
I understand that I can discuss this research study at any time with the principal 
investigator, Dr. Ben Hurley at (301) 405-2457 or with the study coordinator of this 
project at (301) 405-2569. 
I have read and understand the above information and have been given an 
adequate opportunity to ask the investigators any questions I have about the study. My 
questions, if any, have been answered by the investigators to my satisfaction. By my 
signature I am indicating my decision to consent to participate voluntarily in this study. 
 
Principal investigator: Ben Hurley, Ph.D., Dept of Kinesiology, HLHP Building, 
University of Maryland, College Park, MD 20742-2611, Ph: (301) 405-2486. 
 
Printed Name of Subject__________________________________ 
 
Signature of Subject_____________________________________ Date______________ 
 
Contact information of Institutional Review Board: If you have questions about your 
rights as a research subject or wish to report a research-related injury, please contact: 
Institutional Review Board Office, University of Maryland, College Park, MD 20742; 




Data Entry #1_____________Date___________Initials 




Subject Name____________________ ID___________ Date__________________ 
 
Tech Initials_____________________ Time_________ Baseline  /  After ST 
 
1. Are you allergic to latex?      Yes /  No 
2. Have you fasted overnight?      Yes  /  No 
3. Did you have a cold, flu, dental infection or other infection  Yes  /  No 
 in the last 2 weeks?  
If yes, (  ) within one week?  (  ) within 48 hours? 
4. Do you have any seasonal allergies?     Yes  /  No 
 If yes, please describe any symptoms in the last 48 hours 
 ______________________________________________________________ 
5. Did you seek medical attention for a cold, flu, or infection   Yes  /  No 
in the past month?  
 If yes, what was the diagnosis______________________________________ 
6. Have you taken any pain medications within the last 48 hours?  Yes  /  No 
7. Do you require us to use a specific arm for all blood draws?  Yes  /  No 
 If yes, please specify which arm you need us to use_____________________ 
8. Have you ever fainted or felt dizzy/nauseous during a blood draw? Yes  /  No 
 





Tube Type: Purple Top  /  Tiger Top  /  Red Top 
Hemoglobin #1________________  Hemoglobin #2________________ 
Hemoglobin #2________________  Hematocrit #2________________ 







DEXA Body Scan-USDA 
 
 
Name:___________________________ Subject Number:____________ 
 
Date:_____________ Time:_________ am/pm Gender: M / F 
 
Date of Birth:____________________________________ 
 
Height:___________________ inches                     _______________ cm 
 
Weight:___________________ lbs.                         _______________ kg 
 
Dominant Leg: R / L 
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Knee Extensor 1RM 
 
Baseline / Posttest 
 
Subject ID ______________      Date__________________ Seat_____ 
 
Examiners Initials______ Body weight_________ Age_______ Resting BP________ 
 
Participant’s initials indicating that the P/D and RPE scale is understood and that he/she 
has the right to stop the test at anytime ________   
        Right leg / Left leg 
 
  Resistance         P/D scale         RPE scale 
  ____0____          ______________________             ________ 
 
Set 1  _________          ______________________        ________ 
Set 2  _________          ______________________        ________ 
Set 3  _________          ______________________              ________ 
Set 4  _________               ______________________        ________ 
Set 5  _________          ______________________        ________ 
Set 6  _________          ______________________        ________ 
Set 7  _________          ______________________        ________ 
Set 8  _________          ______________________        ________ 
Set 9  _________          ______________________        ________ 
Set 10  _________          ______________________        ________ 
Set 11   _________          ______________________        ________ 
Set 12  _________          ______________________        ________ 
Most severe P/D:  ______  Subject’s initials:  _______ Valid        Invalid 
 




Data entry #1:________initials __________date 
 





Chest Press 1RM 
 
Baseline / Posttest 
 
Subject ID ______________      Date__________________ Seat_____ 
 
Examiners Initials______ Body weight_________ Age_______ Resting BP________ 
 
Participant’s initials indicating that the P/D and RPE scale is understood and that he/she 
has the right to stop the test at anytime ________  
 
  Resistance         P/D scale         RPE scale 
  ____0____          ______________________             ________ 
 
Set 1  _________               ______________________        ________ 
Set 2  _________          ______________________        ________ 
Set 3  _________          ______________________              ________ 
Set 4  _________               ______________________        ________ 
Set 5  _________          ______________________        ________ 
Set 6  _________          ______________________        ________ 
Set 7  _________          ______________________        ________ 
Set 8  _________          ______________________        ________ 
Set 9  _________          ______________________        ________ 
Set 10  _________          ______________________        ________ 
Set 11   _________          ______________________        ________ 
Set 12  _________          ______________________        ________       
Most severe P/D:  ______  Subject’s initials:  _______ 
Post BP____________ Valid        Invalid 
 
If invalid, please explain: ________________________________________________ 
_____________________________________________________________________ 
Muscle Endurance Test 
 
70% 1 RM ______ Valid Invalid 
 
Number of Reps______ 
Data entry #1:________initials_______Date 
 






Leg Press 1RM 
 
Baseline / Posttest 
 
Subject ID ______________      Date__________________ Seat_____ 
 
Examiners Initials______ Body weight_________ Age_______ Resting BP________ 
 
Participant’s initials indicating that the P/D and RPE scale is understood and that he/she 
has the right to stop the test at anytime ________  
 
  Resistance         P/D scale         RPE scale 
  ____0____          ______________________             ________ 
 
Set 1  _________               ______________________        ________ 
Set 2  _________          ______________________        ________ 
Set 3  _________          ______________________              ________ 
Set 4  _________               ______________________        ________ 
Set 5  _________          ______________________        ________ 
Set 6  _________          ______________________        ________ 
Set 7  _________          ______________________        ________ 
Set 8  _________          ______________________        ________ 
Set 9  _________          ______________________        ________ 
Set 10  _________          ______________________        ________ 
Set 11   _________          ______________________        ________ 
Set 12  _________          ______________________        ________       
Most severe P/D:  ______  Subject’s initials:  _______ 
Post BP____________ Valid        Invalid 
 
If invalid, please explain: ________________________________________________ 
_____________________________________________________________________ 
Muscle Endurance Test 
 
70% 1 RM ______ Valid Invalid 
 
Number of Reps______ 
Data entry #1:________initials_______Date 
 








Baseline / Posttest 
 
Subject ID ____________________________ Date ____________________ 
Tester _______________________________ Time ____________________   
 
Resting BP: ___/___mmHg    
Seat Position:____ 1-RM R:_____      Converted 1-RM :  R: _____ 
   1-RM L :_____      Converted 1-RM :  L: _____ 
























50         ex. 
EDH_001_P1 50       
50       
60         
60       
60       
70         
70       
70       
Constant Reminders: Back against seat 
   Look straight ahead 
   Breathe Normally 
 
 
General Comments: _____________________________________________ 
______________________________________________________________ 
 






Most Severe P/D __________ Subject’s Initials _______________ 
Data entry #1:_______initials_______Date 
 





Data Entry #1_____________Date___________Initials 
Data Entry #2_____________Date___________Initials 
Maryland CARES 
Physical Function Testing 
 
Baseline / After Training 
 
Subject Name____________________ ID___________ Date__________________ 
 
Examiner_______________________ Resting BP________ Initial P/D________ 
 
6m usual walk 
 Trial #1___________________________   P/D________ 
  30 sec rest 
 Trial #2___________________________  P/D________ 
  1 min rest 
Comments__________________________________________________________________ 
 
6m Rapid walk 
 Trial #1___________________________  P/D________ 
  30 sec rest 
 Trial #2___________________________  P/D________ 
  2 min rest 
Comments__________________________________________________________________ 
 
8 foot Get up and Go 
Trial #1___________________________  P/D________ 
  1 min rest 
 Trial #2___________________________  P/D________ 
  2 min rest 
Comments__________________________________________________________________ 
 
30 second chair stands 
 Trial #1___________________________  P/D________ 




Trial #1___________________________  P/D________ 
  1 min rest 
 Trial #2___________________________  P/D________ 














University of Maryland CARES-Full Body Strength Training Log 
 





          
  
 


























             
             
             
             
 
 
            
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             




Pain / Discomfort Rating Scale 
 
0 No significant pain or discomfort 
1 Slight or minimal pain 
2 Moderate or bothersome pain 
3 More than moderate but less than severe pain 
4 Somewhat severe pain 
5 Severe pain 
6 Very severe pain 
 
Comments: 
Date Pain Joint(s) Affected? Which exercises?  Treatment Plan 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





























Appendix III: Raw Data 

















RefCon1 71 180.0 89.9 89.9 27.76 27.74 24.94 25.21 22.4 22.7 
RefCon2 53 161.5 77.2 78.8 29.61 30.21 30.88 30.06 23.8 23.7 
RefCon3 59 161.8 83.0 81.5 31.70 31.15 23.41 22.21 19.4 18.1 
RefCon4 70 184.9 89.5 91.0 26.18 26.63 28.23 26.27 25.3 23.9 
RefCon5 64 173.2 81.1 82.8 27.02 27.59 20.06 19.21 16.3 15.9 
RefCon6 71 162.0 74.6 75.5 28.41 28.77 32.51 29.61 24.2 22.4 
RefCon7 68 171.5 84.1 84.4 28.58 28.70 25.03 25.26 21.0 21.3 
RefCon8 55 175.3 125.3 122.3 40.81 39.81 34.71 34.40 43.5 42.1 
RefCon9 56 170.2 99.7 100.2 34.42 34.61 29.64 27.69 29.6 27.8 
RefCon10 56 167.6 88.6 89.5 31.52 31.86 23.14 21.64 20.5 19.4 
RefCon11 61 172.7 76.5 75.0 25.63 25.12 26.47 25.83 20.2 19.4 
RefCon12 52 178.9 66.7 68.5 20.83 21.39 22.29 20.73 14.9 14.2 
RefCon13 74 182.8 78.9 80.3 23.62 24.04 18.84 20.95 14.9 16.8 
RefCon14 61 177.8 90.3 89.1 28.56 28.20 28.24 28.50 25.5 25.4 
RefCon15 62 169.4 99.0 98.7 34.48 34.39 25.84 23.42 25.6 23.1 
RefCon16 51 188.9 96.6 97.3 27.07 27.26 25.93 28.08 25.0 27.3 
RefCon17 67 183.9 113.7 111.1 33.63 32.85 28.56 28.89 32.5 32.1 
RefCon18 54 191.0 106.2 107.7 29.12 29.53 31.08 31.40 33.0 33.8 
RefCon19 57 168.2 92.6 92.7 32.75 32.77 26.42 27.35 24.5 25.4 
RefCon20 56 171.7 106.6 108.3 36.16 36.72 30.83 29.05 32.9 31.4 
                      
PCa 10 67 182.4 117 118.8 35.37 35.86 38.0 38.6 44.7 46.1 
PCa 11 77 167.2 76.9 79.2 27.72 28.63 29.9 29.4 23.2 23.5 
PCa 12 62 185.1 154.3 159.7 44.66 45.92 44.9 45.4 68.7 71.4 
PCa 13 58 183.5 104.9 108.6 31.20 32.50 32.4 32.4 34.1 35.4 
PCa 14 60 164.6 102.5 106.2 37.74 39.14 39.4 38.5 40.3 40.8 
PCa 15 74 167.1 75.3 76.3 27.22 27.54 30.3 28.6 23.0 22.0 
PCa 16 66 184.1 89.1 89.2 26.67 26.51 29.5 27.8 26.6 24.9 
PCa 17 62 167.6 80.4 83 28.82 29.69 23.4 24.2 18.9 20.2 
PCa 18 77 169.2 95.7 96.1 33.71 33.86 26.3 25.1 25.4 24.4 
PCa 20 72 174.7 97.1 97.9 32.03 32.17 33.2 32.4 32.5 31.8 
PCa 21 64 167.7 81.1 82.1 28.83 29.18 30.6 30.0 24.8 24.6 
PCa 22 61 174.3 101.6 101.6 33.72 33.47 30.6 28.8 31.3 29.3 
PCa 23 62 166.4 81.4 84.5 29.57 30.59 26.6 24.5 21.8 20.8 
PCa 24 67 166 109.4 109.7 39.62 39.80 36.8 36.1 40.2 39.6 
PCa 25 73 171.4 102.4 101.2 35.17 34.78 31.5 30.2 32.5 30.8 
PCa 26 80 177.1 80.8 83 25.98 25.38 20.2 21.5 16.4 18.0 
PCa 28 64 169.9 91.1 86.8 31.56 30.54 30.2 28.6 26.7 25.4 



















Pre     
MV ‡ 
Post   
MV ‡ 
RefCon1 3.0 3.0 67.5 67.2 36.3 56.2 1985.4 2148.6 
RefCon2 2.2 2.2 53.4 55.1 37.5 42.3 1580.8 1755.5 
RefCon3 2.3 2.4 63.6 63.4 22.4 28.8 1815.3 1908.7 
RefCon4 3.0 3.0 64.2 67.1     2245.2 2372.1 
RefCon5 3.2 3.2 64.8 66.9 37.5 47.5 1996.7 2309.7 
RefCon6 2.3 2.3 50.3 53.1 30.5 39.2 1572.3 1765.5 
RefCon7 2.7 2.7 63.0 63.1 25.9 36.1 1651.7 1846.6 
RefCon8 3.0 3.0 81.8 80.2 51.7 56.5 2689.3 2706.0 
RefCon9 3.1 3.1 70.1 72.5 39.8 65.2 2535.8 2997.1 
RefCon10 2.7 2.7 68.1 70.2 38.2 60.2 2151.0 2477.5 
RefCon11 2.7 2.6 56.2 55.6 26.7 38.0 1877.3 1922.2 
RefCon12 2.0 2.0 51.8 54.3 28.8 37.1 1568.0 1843.9 
RefCon13 3.1 3.1 64.1 63.5 34.0 40.2 1754.2 1983.4 
RefCon14 2.7 2.7 64.8 63.7 48.6 48.6 2020.2 2290.9 
RefCon15 2.7 2.7 73.4 75.6 31.9 35.0 2032.1 2191.8 
RefCon16 3.4 3.5 71.6 70.0 35.9 53.8 2391.1 2645.5 
RefCon17 3.7 3.7 81.3 79.0 51.7 56.9 2562.8 2744.1 
RefCon18 3.5 3.6 73.2 73.9 53.8 58.9 2599.8 2839.2 
RefCon19 2.6 2.6 68.2 67.4 41.3 47.5 2206.3 2477.0 
RefCon20 3.3 3.3 73.7 76.8 45.4 50.6 2680.0 2848.8 
                  
PCa 10 3.5 3.5 69.5 69.7 26.7 34.2 5089.3 5432.0 
PCa 11 2.2 2.1 52.1 54.4 23.6 24.2 3467.5 3844.1 
PCa 12 3.6 3.1 80.7 82.9 27.8 36.1 5009.8 5298.8 
PCa 13 3.6 3.6 67.4 70.4     4016.0 4454.6 
PCa 14 3.1 3.1 58.8 62.1 20.5 35.0 3932.0 4261.8 
PCa 15 2.1 2.1 50.8 52.8     2408.6 2658.0 
PCa 16 2.9 2.9 60.8 62.0 28.4 38.2 4103.0 4489.2 
PCa 17 3.2 3.1 58.8 60.1 38.2 45.9 3754.3 4119.4 
PCa 18 3.4 3.4 67.7 69.1 23.6 30.5 3908.5 4004.3 
PCa 20 2.4 2.3 62.9 64.0 28.8 37.1 4339.1 4460.7 
PCa 21 2.8 2.7 53.5 54.7 28.8 36.7 3479.9 3613.9 
PCa 22 3.1 3.1 68.0 69.2 27.8 39.2 4536.7 4810.3 
PCa 23 1.8 1.8 58.2 62.1 30.5 40.7 4124.8 4440.4 
PCa 24 3.8 3.8 65.1 66.3 30.9 33.4 4263.5 4389.3 
PCa 25 3.2 3.3 67.6 68.1 27.8 35.0 4677.3 4844.4 
PCa 26 3.4 3.3 61.7 62.2 31.1 34.2 3406.1 3524.8 
PCa 28 4.0 4 57.7 59.6 20.5 29.9     
BMC = Bone Mineral Content; FFM = Fat Free Mass; KE 1RM = Knee Extension Maximal Strength; MV 























RefCon1                 
RefCon2                 
RefCon3             394.4 529.7 
RefCon4                 
RefCon5 544.5 506.3 544.5 567.5 596.5 560.7     
RefCon6 510.5 519.2 476.5 519.2 510.5 555.1 479.6 558.5 
RefCon7             371.4 370.2 
RefCon8 720.9 761.2 720.9 699.7 724.7 695.8 730.4 599.9 
RefCon9                 
RefCon10 684.2 801.7 633.6 801.7 684.2 775.1 679.5 622.0 
RefCon11 411.4 434.4 428.4 434.4 411.4 422.0 463.5 390.1 
RefCon12 318.7 437.3 360.8 437.3 318.7 450.5 269.3 430.2 
RefCon13 437.0 462.8 429.9 462.8 437.0 397.6 423.3 364.2 
RefCon14 685.3 684.1 685.3 684.1 658.7 653.3 622.0 607.9 
RefCon15 448.1 396.4 448.1 462.6 515.7 471.0 517.7 475.2 
RefCon16                 
RefCon17 526.7 494.9 526.7 531.3 518.0 499.3 453.6 460.4 
RefCon18 664.9 656.9 664.9 715.4 699.0 769.4 717.5 778.9 
RefCon19 684.6 729.6 614.0 692.7 681.0 729.6 672.9 722.3 
RefCon20 569.7 670.0 568.6 679.7 547.7 659.7 528.7 659.1 
                  
PCa 10     395.7 402.1 410.6 412.1 408.9 415.5 
PCa 11 310.7 327.2 310.7 327.2 338.3 357.6 342.3 389.3 
PCa 12 303.6 423.2 291.8 423.2 303.6 403.7 401.5 400.1 
PCa 13                 
PCa 14 344.2 378.5 344.2 416.3 362.6 390.2 365.1 407.2 
PCa 15 240.4 290.2 240.4 290.2 234.1 329.1 226.9 313.8 
PCa 16 412.3 435.8 381.6 469.9 412.3 451.7 411.3 418.5 
PCa 17 454.8 544.6 481.1 544.6 454.8 538.8 409.2 491.1 
PCa 18 290.8 326.4 301.1 326.4 290.8 355.5 315.0 390.4 
PCa 20 312.2 366.1 287.0 366.1 312.2 378.9 317.6 377.8 
PCa 21 415.3 479.5 421.6 479.5 415.3 495.0 430.8 507.7 
PCa 22 383.4 411.4 363.7 411.4 411.8 429.0 383.4 384.1 
PCa 23 417.2 550.4 379.3 538.9 417.2 529.1 515.5 539.6 
PCa 24 278.1 257.3 278.1 268.8 286.0 267.9 265.6 254.0 
PCa 25 361.2 408.1 351.9 408.1 361.2 411.9 370.6 407.4 
PCa 26 348.6 358.9 348.6 360.2 353.8 369.6 317.6 332.1 
PCa 28 194.0 274.0 209.0 274.0 210.0 250.0 194.0 231.0 
PPAbs = Absolute Peak Power; PP50, 60, 70 L = Peak power at 50,60, and 70% of KE 1RM; ‡ = Trained 























RefCon1     111.9 146.1 136.8 175.0 160.6 203.4 
RefCon2                 




  75.1 86.6 
RefCon4                 
RefCon5 84.3 82.4 84.3 96.9 97.2 112.4 
 
  
RefCon6 83.3 82.8 72.6 82.8 83.3 101.9 94.2 117.9 
RefCon7             76.2 102.4 
RefCon8 108.9 111.4 108.9 129.5 128.4 138.7 146.3 158.6 
RefCon9                 
RefCon10 93.8 117.5 81.0 117.5 93.8 138.6 107.1 154.9 
RefCon11 73.1 83.6 65.5 83.6 73.1 94.1 84.4 107.9 
RefCon12 64.2 64.1 64.2 73.6 73.9 90.5 84.2 104.7 
RefCon13 85.0 85.4 72.7 85.4 85.0 98.4 97.8 112.4 
RefCon14 104.8 100.8 104.8 100.8 122.3 119.1 140.1 117.2 
RefCon15 77.1 72.2 77.1 80.0 90.4 95.0 101.3 109.7 
RefCon16                 
RefCon17 283.2 286.0 283.2 303.1 334.6 362.4 385.7 429.0 
RefCon18 290.3 296.1 290.3 326.1 346.0 382.2 403.2 445.7 
RefCon19 323.5 330.6 241.9 275.1 278.9 330.6 323.5 374.6 
RefCon20 258.1 256.6 258.1 285.9 324.2 332.7 364.3 385.4 
                  
PCa 10     169.5 198.4 192.6 232.0 218.9 272.0 
PCa 11 154.6 155.6 154.6 155.6 175.2 176.2 194.5 197.8 
PCa 12 191.5 198.7 168.9 198.7 191.5 245.2 220.7 276.5 
PCa 13                 
PCa 14 145.1 149.8 145.1 210.2 163.4 237.5 181.4 274.8 
PCa 15 128.6 133.2 128.6 133.2 141.8 154.4 157.5 168.7 
PCa 16 202.2 203.1 179.1 221.0 202.2 258.2 233.0 296.1 
PCa 17 255.6 265.7 216.2 265.7 255.6 306.6 299.0 353.5 
PCa 18 173.2 176.6 154.1 176.6 173.2 198.2 195.0 233.4 
PCa 20 195.7 199.1 172.5 199.1 195.7 247.7 228.8 291.6 
PCa 21 204.2 208.4 181.2 208.4 204.2 252.6 236.5 291.5 
PCa 22 224.6 225.3 172.2 225.3 195.4 266.7 224.6 310.3 
PCa 23    184.8 234.1  277.3 193.6 319.1  228.8 
PCa 24    181.5 189.2  220.7 198.5  255.6 235.9 
PCa 25 197.0 200.4 172.6 200.4 197.0 241.0 228.0 279.6 
PCa 26 186.8 183.0 186.8 195.3 219.6 235.2 253.7 266.0 
PCa 28                 
PTAbs = Absolute Peak Torque; PT50, 60, 70 = Peak Torque at 50, 60, & 70% of KE 1RM; ‡ = Trained 























RefCon1     5.3 3.2 4.3 2.4 2.9 1.9 
RefCon2                 




  5.4 6.2 
RefCon4                 
RefCon5 6.9 6.1 6.9 5.9 6.4 5.1 
 
  
RefCon6 6.3 6.4 6.9 6.4 6.3 5.5 5.3 4.9 
RefCon7             5.0 3.7 
RefCon8 6.7 7.0 6.7 5.4 5.8 5.1 5.1 3.8 
RefCon9                 
RefCon10 7.5 7.1 8.0 7.1 7.5 5.6 6.4 4.2 
RefCon11 5.7 6.0 6.5 5.4 5.7 4.7 5.5 3.8 
RefCon12 6.0 5.7 6.0 5.9 4.7 5.0 3.5 4.2 
RefCon13 5.2 5.4 6.0 5.4 5.2 4.2 4.4 3.4 
RefCon14 6.5 6.8 6.5 6.8 5.5 5.6 4.5 5.2 
RefCon15 5.8 5.5 5.8 5.8 5.7 5.0 5.1 4.4 
RefCon16                 
RefCon17 5.1 4.9 5.1 4.9 4.2 3.9 3.4 3.2 
RefCon18 6.4 6.1 6.4 6.1 5.6 5.5 4.8 4.8 
RefCon19 5.8 6.0 7.2 6.9 6.9 6.0 5.8 5.3 
RefCon20 6.2 7.2 6.2 6.6 5.0 5.5 4.3 4.6 
                  
PCa 10     6.4 5.6 5.8 4.9 5.1 4.2 
PCa 11 5.5 5.8 5.5 5.8 5.3 5.6 4.8 5.4 
PCa 12 4.3 5.8 4.7 5.8 4.3 4.5 5.0 4.0 
PCa 13                 
PCa 14 6.5 6.9 6.5 5.5 6.1 4.5 5.5 4.0 
PCa 15 5.1 6.0 5.1 6.0 4.7 5.8 4.1 5.1 
PCa 16 5.6 5.9 5.9 5.8 5.6 4.8 4.8 3.9 
PCa 17 4.9 5.6 6.4 5.6 4.9 4.9 3.9 3.9 
PCa 18 4.6 5.1 5.4 5.1 4.6 4.9 4.4 4.6 
PCa 20 4.4 5.0 4.6 5.0 4.4 4.2 3.8 3.5 
PCa 21 5.7 6.3 6.4 6.3 5.7 5.4 5.0 4.8 
PCa 22 4.7 5.0 5.9 5.0 5.8 4.4 4.7 3.4 
PCa 23 5.3 6.9 5.7 6.3 5.3 5.3 5.7 4.7 
PCa 24 4.2 3.9 4.2 4.0 3.7 3.3 3.0 2.8 
PCa 25 5.0 5.6 5.6 5.6 5.0 4.7 4.5 4.1 
PCa 26 5.1 5.3 5.1 5.1 4.5 4.4 3.5 3.5 
PCa 28                 
PVAbs = Absolute Peak Velocity; PV50, 60, 70 = Peak Velocity at 50, 60, & 70% of KE 1RM; ‡ = 






ID Pre SCF ‡ Post SCF ‡ Pre IMF ‡ Post IMF ‡ 
RefCon1 36.3 36.9 4.1 5.4 
RefCon2 58.8 67.0 5.0 4.8 
RefCon3 38.1 34.9 3.0 3.5 
RefCon4 39.8 39.4 2.3 2.5 
RefCon5 30.2 33.8 4.5 4.4 
RefCon6 44.1 45.8 7.2 7.2 
RefCon7 53.8 52.2 4.8 4.4 
RefCon8 118.1 117.0 14.4 13.7 
RefCon9 91.2 81.4 11.6 10.8 
RefCon10 36.5 39.7 4.8 5.4 
RefCon11 41.0 39.5 3.6 3.2 
RefCon12 40.2 40.1 4.4 3.1 
RefCon13 34.0 35.2 2.4 3.8 
RefCon14 53.5 56.0 10.4 7.5 
RefCon15 32.2 34.3 7.1 7.0 
RefCon16 53.6 58.5 6.5 6.8 
RefCon17 103.1 99.3 6.7 6.5 
RefCon18 69.0 72.9 9.0 8.5 
RefCon19 83.5 83.0 9.3 8.7 
RefCon20 82.0 85.4 5.8 6.1 
          
PCa 10 153.0 156.4 11.8 11.0 
PCa 11 61.4 64.9 7.6 6.9 
PCa 12 307.9 287.8 14.9 17.0 
PCa 13 112.2 109.8 7.6 7.8 
PCa 14 97.7 100.0 10.1 9.4 
PCa 15 54.1 54.1 3.1 3.3 
PCa 16 72.4 68.5 6.3 6.1 
PCa 17 43.9 47.1 2.5 2.6 
PCa 18 60.4 52.1 9.1 7.3 
PCa 20 101.4 108.5 8.6 8.5 
PCa 21 67.3 73.2 6.1 6.0 
PCa 22 104.9 100.9 5.7 3.9 
PCa 23 65.3 62.0 5.5 4.7 
PCa 24 162.4 162.9 13.0 12.3 
PCa 25 84.8 82.8 11.6 11.2 
PCa 26 316.9 337.0 3.5 3.7 
PCa 28         







       
ID PCa Diagnosis ADT days LHRHa Anti-A Rad Prost 
PCa 10 4002 4002 Y N Y N 
PCa 11 2574 2392 Y N Y N 
PCa 12 4639 4548 Y N N N 
PCa 13 3581 296 N Y Y N 
PCa 14 2826 514 Y Y N Y 
PCa 15 6989 3181 Y N Y N 
PCa 16 2081 1008 Y N Y Y 
PCa 17 3350 501 Y N N Y 
PCa 18 886 802     Y N 
PCa 20 6665 1282 Y N N Y 
PCa 21 375 254 Y N Y N 
PCa 22 1550 728 Y Y N Y 
PCa 23 972 900 Y N Y N 
PCa 24 4543 1957 Y Y N N 
PCa 25 989 559 Y N Y N 
PCa 26 1302 256 Y N N N 
PCa 28 768 514 Y N N N 
PCa Diagnosis = Days Since Diagnosis; ADT days = Length of ADT treatment; LHRHa = Luteinizing 
Hormone  Releasing Hormone agonist; Anti-A = Anti-Androgen; Rad = Radiotherapy; Prost = 
Prostatectomy 
       
 
 
Pre Post Pre Post Pre Post Pre Post 
ID Free T Free T PSA PSA Hb Hb Hct Hct 
PCa 10 0.91 1.00 U/D U/D 13.3 14.0 35.0 35.0 
PCa 11 0.99 1.40 U/D U/D 12.2 14.1 36.3 37.7 
PCa 12 0.28 U/D U/D U/D 11.7 12.5 37.7 32.7 
PCa 13 1.14 0.95 U/D 0.14 15.2 14.0 40.0 43.0 
PCa 14 0.85 0.70 U/D U/D 12.0 10.8 33.0 37.0 
PCa 15 0.83 0.51 0.28 0.33 15.8 13.5 46.0 41.0 
PCa 16 0.73 1.11 U/D 0.06 13.6 12.5 37.7 41.3 
PCa 17 2.29 13.60 U/D U/D 12.3 12.0 38.3 30.3 
PCa 18 5.83 5.47 U/D U/D 12.1 11.8 34.0 39.3 
PCa 20 
        
PCa 21 1.52 1.21 0.80 0.14 13.2 11.9 39.8 36.3 
PCa 22 U/D U/D U/D U/D 13.1 12.7 42.0 40.7 
PCa 23 0.30 U/D U/D U/D 12.4 13.0 37.3 38.7 
PCa 24 U/D U/D 0.65 0.91 11.7 11.6 38.3 39.7 
PCa 25 U/D U/D U/D U/D 11.4 13.0 38.7 36.3 
PCa 26 U/D U/D U/D U/D 12.8 13.7 40.7 38.0 
PCa 28 
        





































PCa 10 34.0 30.9 52.2 53.1 213.2 238.1 8 8 16 30 
PCa 11 21.5 20.5 40.8 49.9 217.7 222.3 12 20 15 25 
PCa 12 27.8 29.9 38.6 65.8 208.7 303.9 15 33 20 39 
PCa 13 19.5 26.7 51.3 59.0 149.7 206.4 11 21 50 72 
PCa 14 23.6 27.8 52.2 59.0 265.4 288.0 13 20 14 30 
PCa 15 23.0 29.6 47.6 52.2 149.7 220.0 10 16 9 55 
PCa 16 30.9 35.7 40.8 44.0 203.2 272.2 10 20 15 35 
PCa 17 34.0 44.4 70.3 79.4 267.6 303.9 16 24 14 32 
PCa 18 20.1 27.8 56.7 68.0 240.4 288.0 17 23 23 40 
PCa 20 29.9 35.9 54.4 59.9 186.0 240.4 10 15 11 20 
PCa 21 26.3 30.5 47.6 59.0 190.5 267.6 15 23 25 30 
PCa 22 31.9 44.4 56.7 68.0 222.3 281.2 11 20 15 30 
PCa 23   49.0 59.0 220.0 256.3 12 21 14 30 
PCa 24 29.9 30.9 49.9 54.4 242.7 249.5 10 15 20 25 
PCa 25 38.2 41.3 50.3 63.5 213.2 272.2 10 20 9 67 
PCa 26 34.8 37.1 45.4 50.8 183.7 199.6 13 20 12 30 
PCa 28 17.4 23.6 36.3 49.9 204.1 272.2 

































463.5 435.4 467.7 437.6 439.8 449.4 4910.2 5191.4 
PCa 11 267.9 323.7 267.9 323.7 297.9 348.5 301.4 374.4 3225.9 3667.0 
PCa 12 270.0 381.3 270.0 381.3 296.2 382.1 215.2 390.1 4995.0 5301.3 
PCa 13 
  
251.5 280.4 261.9 309.2 264.6 320.5 4169.3 4667.3 
PCa 14 309.1 349.1 301.3 349.1 309.1 335.5 312.9 325.0 3664.9 4087.9 
PCa 15 322.6 369.7 328.9 369.7 322.6 361.1 319.7 347.0 2816.3 3050.4 
PCa 16 407.5 414.5 391.5 414.5 407.5 419.4 412.0 414.5 4004.1 4193.8 
PCa 17 411.1 487.9 419.8 483.0 411.1 461.4 381.5 404.4 3799.0 4089.1 
PCa 18 303.2 314.5 290.3 314.5 303.2 311.2 324.9 364.9 3821.5 4084.0 
PCa 20 375.6 376.4 288.4 376.4 375.6 385.7 344.6 370.9 4136.5 4191.1 
PCa 21 385.3 400.3 379.7 378.2 380.8 400.3 385.3 366.1 3621.4 3736.7 
PCa 22 354.5 416.6 351.8 416.6 423.3 395.6 354.5 312.1 4773.0 5061.2 
PCa 23 355.4 485.5 
      
3863.9 4176.1 
PCa 24 
        
4116.9 4289.8 
PCa 25 430.1 480.6 430.1 466.2 440.7 474.7 458.1 451.3 4712.0 4878.6 
PCa 26 380.1 389.7 380.1 388.3 368.5 382.0 332.6 361.4 3516.2 3658.3 
PCa 28     183.0 253.0 162.0 224.0 172.0 240.0     
PPAbs L = Absolute Peak Power for the L Leg; PP50, 60, 70 L = Peak power at 50,60, and 70% of KE 







Pre Pre Pre Post Post Post 
ID Upper BMD Lower BMD BMD Upper Lower BMD 
PCa 10 1.249 1.343 1.275 1.259 1.407 1.299 
PCa 11 0.916 1.132 1.012 0.923 1.088 0.995 
PCa 12 1.521 1.344 1.477 1.054 1.258 1.289 
PCa 13 1.337 1.425 1.381 1.312 1.385 1.348 
PCa 14 1.314 1.360 1.340 1.308 1.350 1.312 
PCa 15 1.005 1.008 1.024 0.998 1.029 1.028 
PCa 16 1.051 1.227 1.139 1.079 1.263 1.171 
PCa 17 1.272 1.455 1.363 1.248 1.388 1.318 
PCa 18 1.269 1.600 1.435 1.299 1.600 1.449 
PCa 20 0.955 1.095 1.037 0.926 1.105 1.028 
PCa 21 1.207 1.206 1.185 1.198 1.189 1.181 
PCa 22 1.184 1.489 1.296 1.213 1.523 1.313 
PCa 23 0.855 0.983 0.928 0.817 0.992 0.910 
PCa 24 1.428 1.484 1.430 1.472 1.455 1.445 
PCa 26 
      
PCa 27 
      
PCa 28 1.272 1.647 1.540 1.253 1.629 1.525 















Pre Up & 
Go 
Post Up & 
Go 
PCa 10 4.4 3.7 3.4 2.8 6.1 5.2 
PCa 11 5.7 5.2 3.9 3.3 4.8 5.3 
PCa 12 6.4 4.0 4.9 3.4 10.4 6.2 
PCa 13 5.6 5.0 4.3 4.4 7.4 8.2 
PCa 14 4.4 4.8 3.7 3.2 6.1 5.2 
PCa 15 5.7 6.5 3.9 3.5 5.6 5.8 
PCa 16 6.4 5.1 3.4 3.0 5.0 4.7 
PCa 17 4.5 4.6 3.8 3.2 4.3 4.5 
PCa 18 6.4 4.1 3.9 3.2 5.0 4.9 
PCa 20 5.3 5.1 3.6 3.2 5.5 4.7 
PCa 21 5.0 6.5 3.5 3.1 4.4 4.4 
PCa 22 6.2 5.4 3.5 3.6 5.9 5.4 
PCa 23 6.7 6.5 4.1 3.0 5.8 5.4 
PCa 24 7.1 6.2 4.8 4.4 7.3 7.0 
PCa 25 5.7 4.4 3.6 3.2 5.9 5.4 
PCa 26 6.5 6.4 3.9 3.7 6.1 5.4 
PCa 28 6.4 6.1 3.6 3.5 11.9 9.0 
Usual = Usual Walk; Rapid = Rapid Walk  
       
ID Pre Chair Post Chair Pre Stair Post Stair Pre 400m Post 400m 
PCa 10 14 14 5.0 4.7 284.5 288.4 
PCa 11 13 18 4.1 4.3 266.0 256.6 
PCa 12 7 12 7.4 5.8 426.5 450.1 
PCa 13 12 13 6.4 6.1 299.2 310.2 
PCa 14 17 19 4.9 4.5 294.4 269.2 
PCa 15 14 17 4.8 4.6 297.8 273.5 
PCa 16 13 18 4.5 4.0 241.1 226.5 
PCa 17 20 23 4.0 3.8 242.3 219.2 
PCa 18 14 17 4.2 4.0 257.6 253.5 
PCa 20 16 20 3.7 3.5 301.0 279.6 
PCa 21 17 19 3.9 3.8 270.0 229.9 
PCa 22 17 16 4.1 4.1     
PCa 23 18 21 4.4 3.9 287.2 249.9 
PCa 24 14 17 6.7 6.2 403.3 356.5 
PCa 25 14 16 4.7 4.4 303.3 245.4 
PCa 26 16 17 4.2 4.3 279.4 256.7 
PCa 28 10 13 4.5 3.5 356.4 315.3 






BFI Pre Pre Pre Pre Pre Pre Pre Pre Pre Pre 
ID Q1 Q2 Q3 Q4a Q4b Q4c Q4d Q4e Q4f Total 
PCa 10 4 4 6 3 2 6 1 1 4 31 
PCa 11 4 5 3 5 2 5 4 1 1 30 
PCa 12 9 9 9 10 9 10 9 9 10 84 
PCa 13 3 4 6 2 1 4 2 1 3 26 
PCa 14                   
 
PCa 15 6 5 5 5 6 9 4 8 8 56 
PCa 16 1 3 3 1 
 
1 1 0 0 10 
PCa 17 0 4 4 5 2 1 2 1 3 22 
PCa18 0 0 0 0 0 0 0 0 0 0 
PCa 20 2 6 5 2 2 3 1 1 1 23 
PCa 21  3 0 0 1 1 0 1 0 1 7 
PCa 22 5 6 7 3 0 4 3 0 2 30 
PCa 23 0 0 0 0 0 0 0 0 0 0 
PCa 24 3 5 6 3 3 4 5 2 7 38 
PCa 25 0 6 6 2 0 2 1 0 0 17 
PCa 26 4 7 8 5 7 4 4 5 2 46 
PCa 28 3 5 8 0 3 0 7 0 2 28 
BFI = Brief Fatigue Inventory; Q = Question #1, 2, 3, etc 
           
BFI Post Post Post Post Post Post Post Post Post Post 
ID Q1 Q2 Q3 Q4a Q4b Q4c Q4d Q4e Q4f Total 
PCa 10 0 0 0 0 0 1 1 0 1 3 
PCa 11 1 1 1 1 1 1 2 2 2 12 
PCa 12 7 6 8 8 5 8 8 5 6 61 
PCa 13 0 2 4 0 0 2 2 0 1 11 
PCa 14                     
PCa 15 2 3 3 3 2 2 2 1 3 21 
PCa 16 7 2 2 0 0 0 0 0 0 11 
PCa 17 2 2 2 0 0 0 0 0 0 6 
PCa 18 1 1 1 1 1 1 1 1 1 9 
PCa 20 2 6 5 6 5 5 7 8 10 54 
PCa 21 1 1 2 1 1 1 1 1 0 9 
PCa 22 0 0 2 0 0 1 1 0 1 5 
PCa 23 0 0 0 0 0 0 0 0 0 0 
PCa 24 2 5 7 1 0 6 7 0 3 31 
PCa 25 0 0 0 0 0 0 0 0 0 0 
PCa 26 3 4 6 4 3 2 2 2 2 28 
PCa 28 2 2 6 2 1 2 2 0 2 19 






FACT-P Pre Post Pre Post Pre Post 
ID  PWB PWB SWB SWB EWB EWB 
PCa 10 18 24 24 24 17 19 
PCa 11 22 23 21 19 24 20 
PCa 12 2 8 9 13 2 11 
PCa 13 18 24 18 19 16 19 
PCa 14             
PCa 15 23 21 21 20 13 22 
PCa 16 24 27 17 22 17 14 
PCa 17 17 25 22 26 16 21 
PCa 18 25 24 25 28 24 24 
PCa 20 23 23 26 24 24 16 
PCa 21 22 28 13 23 24 20 
PCa 22 25 27 25 20 17 20 
PCa 23 28 28 12 28 16 20 
PCa 24 19 20 21 19 20 19 
PCa 25 23 25 24 18 24 24 
PCa 26 27 25 28 26 24 24 
PCa 28 20 28 23 23 22 21 
FACT-P = Functional Assessment of Cancer Therapy-Prostate; PWB = Physical Well-Being subsection; 
SWB = Social Well-Being; EWB = Emotional Well-Being 
       
FACT-P Pre Post Pre Post Pre Post 
ID FWB FWB Add Add Total Total 
PCa 10 23 23 35 39 117 129 
PCa 11 20 22 38 38 125 122 
PCa 12 5 13 16 18 34 63 
PCa 13 13 22 17 21 82 105 
PCa 14             
PCa 15 15 14 34 32 106 109 
PCa 16 24 25 37 37 119 125 
PCa 17 18 24 23 35 96 131 
PCa 18 28 27 43 42 145 145 
PCa 20 28 25 38 22 139 110 
PCa 21 24 22 43 38 126 131 
PCa 22 25 26 40 39 132 132 
PCa 23 25 28 48 48 129 152 
PCa 24 15 12 18 25 93 95 
PCa 25 19 19 34 36 124 122 
PCa 26 27 25 37 35 143 135 
PCa 28 18 25 18 28 101 125 

















Table 7.  Post hoc effect size and power estimates for multiple regression. 
Table 8. Post hoc effect size and power estimates for differences between two dependent 





Appendix IV: Power Analysis Tables 
 
Table 7. Post hoc effect size and power estimates for multiple regression. 
 
N R2 IV # Power P value 
Usual Walk - - 0 - - 
Rapid Walk 15 0.66 2 0.99 0.002 
Up & Go 15 0.36 2 0.63 0.083 
Chair Stands 15 0.33 2 0.57 0.088 
Stair Climb 16 0.63 2 0.98 0.002 
400m Walk 16 0.54 2 0.92 0.020 
BFI 16 0.21 1 0.49 0.085 














d Power P value 
FFM 17 1.7 7.5 0.22 0.22 <0.001 
Fat 17 0.1 12.8 0.01 0.05 0.68 
% Fat 17 0.6 6.2 0.10 0.10 0.012 
BMC 17 0.04 0.6 0.07 0.08 0.197 
FACT-P Total 16 7.4 28.0 0.27 0.27 0.043 
FACT-P Physical 16 2.8 6.0 0.46 0.54 0.003 
FACT-P Function 16 1.6 6.3 0.25 0.25 0.069 
BFI 16 10.5 21.4 0.49 0.59 0.011 
KE 1RM R 15 37.0 21.5 1.72 0.99 <0.001 
KE 1RM L 16 22.3 30.1 0.74 0.88 <0.001 
Chest Press 1RM 17 20.1 17.8 1.12 0.99 <0.001 
Leg Press 1RM 17 104.2 73.3 1.42 0.99 <0.001 
CP Endurance 16 7.8 2.6 3.00 0.99 <0.001 
LP Endurance 16 19.3 9.8 1.97 0.99 <0.001 
PP Abs R 15 51.0 34.7 1.47 0.99 <0.001 
PP 50 R 16 57.6 20.3 2.83 0.99 <0.001 
PP 60 R 16 49.7 27.5 1.81 0.99 <0.001 
PP 70 R 16 36.5 34.9 1.05 0.99 <0.001 
PP Abs L 13 47.5 32.8 1.45 0.99 <0.001 
PP 50 L 15 42.2 23.0 1.84 0.99 <0.001 
PP 60 L 15 26.7 31.0 0.86 0.91 0.003 
PP 70 L 15 31.5 38.8 0.81 0.91 0.015 
MV R 16 258.1 666.3 0.39 0.44 <0.001 
MV L 16 261.1 609.0 0.43 0.50 <0.001 
SCF 16 0.1 83.4 0.00 0.05 0.950 
IMF 16 0.4 4.0 0.10 0.10 0.154 
Usual Walk 17 0.5 0.8 0.65 0.82 0.020 
Rapid Walk 17 0.5 0.4 1.19 0.99 <0.001 
Up & Go 17 0.6 2.0 0.32 0.35 0.024 
Chair Stands 17 2.6 3.1 0.83 0.95 <0.001 
Stair Climb 17 0.4 1.1 0.32 0.35 0.002 
400m Walk 16 20.6 52.5 0.39 0.44 <0.001 
FFM = Fat Free Mass; Fat = Fat Mass; BMC = Bone Mineral Content; BFI = Brief 
Fatigue Inventory; KE 1RM = Knee Extensor Maximal Strength; CP/LP Endurance = 
Chest and Leg Press Endurance Tests; PP Abs, 50, 60, 70 = Peak Power at Absolute, 
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Appendix V: Review of Literature 
1. Introduction 
 The incidence of PCa has risen dramatically over the years, with more than 
217,000 new cases estimated to be diagnosed in 2010. It is also estimated that ~32,000 
men will die from PCa in 2010, making it the second leading cause of cancer-related 
death in the U.S. Black men have incidence rates almost 60% higher than white men and 
are twice as likely to die from PCa. The factors directly responsible for these differences 
are currently unknown, although diet, family history, screening frequency, and nationality 
all may contribute. To combat the rising prevalence of PCa, effective treatment strategies 
have been developed to halt or slow tumor growth. Unfortunately, some of these 
strategies are associated with many undesirable side effects which compromise body 
composition, functional independence, and QoL. Recently, exercise interventions, ST in 
particular, have gained in popularity as a means of reducing or even reversing many of 
the treatment related side effects. Therefore, the following review of the literature will 
address the history and prevalence of PCa, racial disparities, treatments and the 
associated side effects of PCa, as well as the role of ST in mitigating these side effects. 
2. PCa History and Background 
 PCa is metastatic tumor that forms in the glandular cells (adenocarcinoma) of the 
prostate (109). It is a slow growing cancer and often remains undetected for years. The 
first description of PCa was in the early 1800’s and was referred to as fungus hematodes, 
a term used at this time to describe all metastatic tumors (123). Over the next century, a 
clearer description of PCa was slow to be established as incidences of PCa were rare and 




became available in the 1970’s and a slow yet steady rise from 1975 through 1988 was 
observed (101). After the U.S. Food and Drug Administration approved PSA testing in 
1986 and it became widely used for PCa screening in 1988, the PCa incidence increased 
sharply and had more than doubled by 1993 (101). The incidence rates fell in 1995 and 
have fluctuated around current levels for the past decade. PCa mortality rates have 
existed for much longer than incidence rates, dating back to 1930. Mortality rates 
doubled over the next 65 years, before experiencing a rapid decline in 1995 and are 
currently comparable to the levels in 1940s (101). Current mortality rates are greatly 
exceeded by the incidence rates, as PCa mortality is 25 men per 100,000 and incidence is 
170 per 100,000 and is the basis for the supposition that men are more likely to die with 
PCa rather than from it. Also in support of this conclusion is that five year survival rates 
of PCa patients are among the highest of all cancers, independent of stage at diagnosis 
(101). Localized and distant stage PCa survival rates are both nearly 100%, but drop to 
31% when the cancer metastasizes (101).   
3. PCa Risk Factors 
 There are many risk factors that contribute to PCa, including age, family history, 
race or ethnicity, nationality, and diet (18, 104, 109).  
3.1 Age. Age is one of the most significant risk factors, as the mortality rate for 
U.S. men who are 65 years of age is approximately three times greater than men who are 
55 years of age, and 22.5 times greater than men who are 45 years of age (1). Similar 
findings were observed for men in the United Kingdom, as the cumulative percentage of 




3.2 Family History. Family history is another factor that influences PCa 
incidence rates. Men who have a brother or father with PCa have a relative risk of 
developing PCa that is 2.5 times greater than those without a family history (102) and the 
greater the number of first degree relatives that were affected, the greater the risk (22). A 
positive family history for PCa is a risk factor that is higher in younger individuals and 
slow declines with age (22, 102). 
3.3 Race and Ethnicity. Race and ethnicity are also related to PCa incidences, as 
U.S. black men have the highest incidence and mortality rates throughout the world (2, 
101). Nationality also plays a role, as incidence rates vary by more than 25 fold across the 
globe (100). For example, U.S. born men have rates twice that of those in Australia and 
Sweden, three times the rate observed in the United Kingdom, and more than ten times 
higher than what is observed in Central and South America and Asia (163). Despite the 
highest incidence rates, the U.S. mortality rate was not different than other developed 
countries but was still higher than those from Asia (163). Interestingly, when Japanese 
men immigrated to the U.S., the mortality ratios were higher than those who had 
remained in Japan (129), which implicates environmental factors, such as diet and 
lifestyles that are related to the particular country. However, immigrants still had lower 
relative mortality risks than U.S. born men for PCa (183), which suggests that genetic 
factors still play an important role. 
3.3 Diet. Diet has also been linked to PCa, although the nutrients responsible for 
impacting PCa risk are less clear. The consumption of dietary fat and red meat increased 
the odds ratios for being diagnosed with PCa (18, 113, 174) while eating foods rich in 




Alcohol consumption elevated PCa risk in moderate (22-56 drinks per week) and heavy 
drinkers (>56 drinks per week) and this risk was similar between black and white men 
(78). Supplementation of micronutrients such as selenium and zinc have also been 
implicated as possible mediators of PCa risk, but the data are inconclusive (18).  
4. Screening for PCa 
 As the relevant risk factors for PCa became known, screening techniques to detect 
PCa early became more common, particularly in high-risk populations. The most widely 
used screening techniques are the digital rectal exam (DRE) and the PSA blood test 
(109), which may be more effective when used together (127) and it appears that more 
men are now taking this approach (166).   
 Human tissue kallikrein 3, more commonly known as PSA, is a serine protease of 
the human tissue kallikrein family (208) and is produced primarily by the epithelial cells 
lining the prostate gland. PSA is released in its inactive form, which is then activated by 
cleaving seven amino acids from the N-terminus and displays chymotrypsin-like 
enzymatic activity (131). The major physiological function of PSA is to cleave the 
seminal vesicle proteins seminogelin I and II (126). PSA has also been identified in 
breast, lung, colon, ovary, liver, kidney, adrenal tumors and biological fluids, such as 
breast and saliva, however, the expression levels are much lower than in the prostate and 
its biological roles in these tissues remains unknown (43). Much of the circulating PSA in 
serum (70 - 90%) complexes with α1-antichymotrypsin with the remaining fraction exists 
as unbound inactive enzyme (free PSA) (191). The sum of the free and bound PSA is 
total PSA, which is used as a biomarker of prostatic tissue damage that can occur with 




produces elevated serum levels which can then be detected. Total and free PSA levels, 
PSA velocity, and PSA density are all used to screen for early detection of PCa (127). 
Total PSA values less than 4.0 ng/mL are considered normal. 
  The DRE is performed as part of a routine exam in men over the age of 50 and in 
high risk patients beginning at age 40 (109, 187). During the exam, an urologist will 
palpate the prostate for abnormalities. If suspicious areas are detected and/or the patient 
has an elevated PSA level, a biopsy can be used to check for PCa histologically (109). 
Unfortunately, with both PSA and the DRE, there are several shortcomings. In particular, 
false positives can lead to psychological distress and additional healthcare expenses while 
false negatives may give PCa patients a false sense of security and the potential inability 
to treat PCa in its earliest stages (4). The lead time for PCa diagnosis has improved by 
several years as a result of DRE and PSA screening procedures (46), although it can vary 
based on the aggressiveness of the tumor. While lead time is crucial for those who have 
aggressive PCa, concerns with overdiagnosis and overtreatment are now being raised (4, 
46). Presently, there is an extensive catalog of research available discussing the screening 
tools and their ability to detect PCa and to reduce mortality, but there is insufficient 
evidence available to provide specific recommendations to the general public regarding 
screening with the PSA or DRE (4, 127, 187). However, those topics are beyond the 
scope of this review. 
5. Racial Disparities  
While the incidence and mortality rates for PCa have declined in recent years, 
there is a striking racial disparity that exists. U.S. black men have the highest incidence of 




than any other racial or ethnic group throughout the world and die of PCa at 2.4 times the 
rate of white men (2, 101). This death rate increases to three times the rate of whites 
when examining men under the age of 65 (1). PCa accounts for ~42% of all cancers 
diagnosed among black men (1). While five year survival rates are similar across race, 
black men have a lower survival if the cancer has metastasized (101). 
A specific reason for this health disparity in PCa mortality has not been 
determined, but several aspects are thought to be involved. One possible physiological 
explanation may be race differences in androgen hormone signaling to the prostate (68, 
146, 156). For example, androgen receptor expression is higher in black vs. white men, 
which may predispose them to higher rates of PCa and related morbidity (68, 156). In 
addition, black men may have higher circulating androgen levels (50, 167, 213), although 
evidence for this is not conclusive (114, 128, 165). Increased androgen receptor 
expression and binding with its primary ligand, testosterone, enhances tumor progression 
in the prostate (193). In support of the hypothesis of increased androgen activity in the 
prostate, healthy black men across the age range had higher total PSA and a trend for 
higher free PSA than white or Hispanic men (120). Alternatively, men with no history of 
PCa had similar PSA levels across black, white, and Asian men, but the percentage of 
individuals with PSA values in excess of 4.0 ng/mL is highest in black men (34). Black 
men with metastatic PCa also had higher PSA levels, more advanced PCa, and were 
diagnosed younger than their white counterparts (194), although it is possible that the 
higher PSA levels and more advanced cancer could be the result of longer intervals 




Racial differences in socioeconomic status, stage at diagnosis, and health 
insurance coverage are additional factors that influence long-term prognosis (104). Of all 
PCa patients, black men routinely had a higher percentage of advanced PCa and were 
poorer, less educated, younger, and had fewer previous screenings than white men (27, 
28, 85, 86, 218). Because income and access to healthcare have be suggested to affect 
survival rates, patients from Veteran Affairs hospitals were studies as this eliminates 
differences in the access to and costs attributable to PCa. Early studies concluded that 
race was not affecting PCa mortality across all ages, but in patients under the age of 65, 
black men had higher mortality (162). Similar findings were observed in another 
investigation using patients from the Veterans Affairs hospital system (57), suggesting 
that when equal access to health care is provided, morality rates may not differ. However, 
both studies reported more advanced PCa in black men, as did others (23, 56). When 
black and white men received treatment from private sector healthcare providers, the 
more advanced PCa still persisted but the probability of survival was lower in black men 
(57). A recent meta-analysis demonstrated that unadjusted all-cause and PCa specific 
mortality rates were higher in black men and the PCa specific mortality rates remained 
elevated after adjusting for age and socio-economic status (52). Because income and 
access to health care do not completely account for differences in tumor progression and 
survival rates, this supports the notion that biological dissimilarities could exist between 
races. This, however, remains controversial as other evidence suggests that after 
correcting for the effect of lower quality treatment and higher mortality due to additional 
illnesses, cancer biology differences between races was unlikely (3, 23, 162). Regardless 




investigators are working to reduce, if not eliminate, the racial differences in PCa 
incidence and mortality rates.  
6. Treatment of PCa 
The overall goal of any cancer treatment is suppress the growth and to prevent the 
spread of the tumor. The currently available treatments for PCa can be divided into two 
basic types, primary and adjuvant treatments. Primary treatments are designed to remove 
or kill the PCa cells and adjuvant treatments are administered to reduce the risk of 
recurrence. Because prostate tumors were discovered before modern pharmacology, 
surgery was initially the only option and still remains a primary method of treatment 
(109, 132). The first prostatectomy procedures were performed in 1905 (216). This 
surgical procedure formed the basis from which many of the current techniques were 
derived (144, 206). Other primary treatments include external beam radiotherapy or 
internal bradytherapy to shrink the tumor (109). Radiotherapy (also referred to as 
radiation therapy or XRT) can also be used in conjunction with a prostatectomy, either in 
the neoadjuvant (before primary treatment) or adjuvant setting. In the early to mid-
portion of the 20th century, it was discovered that PCa tumors were androgen dependent 
(87, 132). This led to the implementation of ADT, initially in the form of surgical (132) 
and later chemical castration (195). Luteinizing hormone releasing hormone agonists 
(LHRHa) and anti-androgen treatment are commonly used adjuvant ADT treatments for 
PCa (109, 179). The abundance of LHRHa causes down-regulation of the gonadotropin 
releasing hormone receptor via negative feedback mechanisms and less production of 
luteinizing hormone in the anterior pituitary and ultimately less testosterone production in 




treatment occurs and tumor progression is closely monitored. This treatment is usually 
reserved for older patients, those with low risk tumors, or in situations where the PCa has 
likely metastasized. Older patients are more likely to use watchful waiting when life 
expectancy is less than ten years and the patient will probably die with PCa, not from it 
(175). The second case when watchful waiting is used is when a patient is diagnosed with 
an advanced stage tumor. If the Gleason score is above eight (scaled from two – ten 
based on tumor cell differentiation) and the tumor grade is T2c or higher (scaled from T1 
– T4 based on tumor size, lymph node, and metastatic progress), these are cases when the 
tumor is advanced and has likely spread. Treatment will not likely significantly extend 
life and the adverse consequences of the side effects may outweigh any potential benefits.  
Racial factors may influence the treatment options. For example, using the 
Surveillance Epidemiology and End Results-Medicare (SEER) database, black men were 
less like to receive ADT than white men following PCa diagnosis and those that did had 
longer wait times until the onset of ADT (28, 86). Aggressive PCa treatment (surgery or 
radiotherapy) was 26% less likely in black men (218) and they were more likely to be 
treated with watchful waiting, even after adjusting for income, marital status, and 
education levels (181). Using a different dataset, white men were again more likely to 
receive aggressive treatment compared with black and Hispanic men with education and 
income levels also adversely affected treatment types (175). The discrepancies regarding 
race may be yet another contributing factor (along with biological and screening 





The effect of each treatment on survival outcomes is an area of contentious debate 
among researchers. Randomized control trials (RCT) using ADT as an adjuvant therapy 
with either radiation or surgery in both local and metastatic PCa patients demonstrate 
significant decreases in mortality compared to patients treated only with a primary 
therapy (16, 140). However, the use of ADT alone does not appear improve prostate-
specific or overall survival in men with localized PCa (44, 130), as in both studies the 
majority of men died from causes other than PCa. Finally, a review of the effectiveness 
and harms of treatments for localized PCa exhibited similar survival rates at five and ten 
years between radiotherapy, brachytherapy, radical prostatectomy, and watchful waiting 
(212). It was not until after 15 or 20 years that watchful waiting and brachytherapy 
showed lower survival. However, very limited numbers of randomized trials comparing 
treatments are available, so this information should be interpreted cautiously (212). Much 
like the debate surrounding screening recommendations, the conflicting reports with 
respect to survival outcomes make establishing guidelines difficult, particularly because 
treatment is influenced by many different factors. However, despite the lack of definitive 
evidence on mortality rates, ADT remains a common treatment option for both local and 
metastatic PCa. 
The effect of androgen suppression in PCa patients was first established in a 
classic study by Huggins and Hodges who examined the effects castration, estrogen, and 
testosterone on serum phosphatases in PCa patients (87). Bilateral orchiectomy resulted 
in a large decline in acid phosphatase levels (an enzyme produced by the prostate that is 
elevated during PCa, similar to PSA) while the addition of testosterone increased acid 




the androgen dependence of PCa tumors. This discovery, along with additional work in 
this area, resulted in the 1966 Nobel Prize in physiology and medicine for Huggins (132). 
ADT was originally permanent, as surgical castration was the sole option. However, in 
1982, LHRHa were given to ten non-metastatic PCa patients. Declines in total 
testosterone and acid phosphatase were observed, along with a decrease in prostate size 
and bone lesions (195) and provided an alternative option to surgical castration. The 
number men electing to undergo surgical castration dropped from 50% to 10% in the 
decade following LHRHa therapies, during which the number of patients on this therapy 
rose to 60% while the remaining 30% did not undergo any form of ADT  (28). 
The use of ADT has continued to increase, yet there are still several issues that 
remain controversial with this treatment, such as the appropriate level of testosterone 
suppression and how frequently testosterone levels should be monitored throughout 
treatment. Historically, castrate levels of total testosterone were considered to be <50 
ng/dL (154), based on sensitivity limitations of the assays used to measure sex hormones 
(24). The development of commercially available radioimmunoassay kits capable of 
accurately measuring total and free testosterone allowed direct measures to replace 
estimates such the free androgen index and calculated free testosterone (210). Using the 
newer methods, Oefelein and colleagues measured testosterone levels in both surgically 
(153) and chemical castrated PCa patients (154). It was rare (5% of patients) that surgical 
patients had total testosterone levels exceeding 20 ng/dL (153) whereas LHRHa patients 
had a greater percentage (13%) who exceeded the 20 ng/dL threshold (154). While this is 
a relatively small difference, the authors suggest that monitoring of testosterone levels 




impact long-term survival. Morote et al. (148) examined the impact of this newer 
castration definition on survival and observed that the lowest testosterone levels that had 
a significant impact on survival was 32 ng/dL as the mean survival dropped from 137 to 
88 months. Another study examined LHRHa administration on a monthly basis vs. the 
standard three month dose and found no differences in patterns of testosterone 
suppression as both groups had mean testosterone levels that were below 20 ng/dL (180). 
Chemical castration compared with surgical castration is likely to remain the preferred 
method ADT because it is reversible and can be administered intermittently, but 
considerations should be given to adopting newer cutoff values, as higher testosterone 
levels may decrease survival. More frequent monitoring may be required to ensure that 
testosterone levels remain suppressed. 
7. Adverse Side Effects 
Although ADT treatment slows the growth of existing tumors, the suppression of 
testosterone leads to numerous physiological and psychological side effects which 
negatively influence the patient’s ability to live an independent, meaningful life. These 
side effects are well documented in the literature and include significant loss of muscle 
strength (6, 65, 211), muscle mass (20, 62, 65, 184-186, 201), a decline in resting energy 
expenditure (136), and BMD (6, 33, 62, 65, 72, 108, 157, 178, 217). PCa patients also 
experience increased fat mass (6, 20, 33, 40, 62, 65, 184-186, 201), fatigue (62, 82, 103, 
119, 190), and anemia (10, 11, 62, 185) with ADT. Men on ADT also have an increased 
number of co-morbidities (40), including insulin resistance (7, 186), glycoslyated 
hemoglobin (186), negative lipoprotein profiles triglycerides (21, 185), and prevalence 




reduced performance in activities of daily living (35, 62, 65, 103, 125) and poorer QoL 
(6, 40, 82, 103, 151, 190). 
7.1 Muscle Mass and Strength. Significant loss of muscle mass is routinely 
observed in the first six to 12 months of ADT in PCa patients (6, 20, 62, 184-186, 201) 
and the longer the treatment period, the greater the loss (125). The decline of total FFM 
during the various length treatments averaged ~2.5% with no change being reported in 
controls (20, 65, 125, 201). The loss of lean mass is likely contributing to lower resting 
energy expenditure after ADT treatment (136). Cross-sectional investigations using 
healthy controls and PCa patients on ADT also revealed substantial group differences in 
upper body (9.6 – 28.4%) and lower body muscle strength (23.7 – 27.9%) (6, 65). 
Ultimately, the loss of muscle mass and strength may be linked to survival as greater 
levels of muscular strength are inversely associated with cancer mortality, independent of 
other risk factors (170). 
7.2 Muscle Power. Muscle power is derived from both the force and speed 
generated during muscular contractions. It is a strong predictor of physical function 
which is necessary for maintaining a high QoL in older adults (80), to an even greater 
extent than muscle strength (8, 9). For this reason, power has the potential to be an 
important QoL indicator for cancer patients. Muscle power declines with advancing age 
(141), even in master’s athletes undergoing ST (155), and is associated with all-cause 
mortality (142). However, the effects of ADT on muscle power have not yet been 
reported in PCa patients. It is hypothesized that muscle power would decline with ADT 




reduce muscle power by adversely affecting the neuromuscular junction and thereby 
interfering with muscle action potentials (211). 
7.3 Bone Mineral Density. Similar to muscle mass and strength, there are 
significant declines in BMD with ADT. Healthy controls and men on ADT have total 
body BMD differences of between 4.5 – 7% (6, 33, 65, 72). Longitudinal examinations 
lasting up to a year revealed smaller losses in BMD (62, 72). These dissimilarities could 
be due to differences in the length of ADT treatment between study designs, as BMD has 
been shown to be inversely related to length of ADT treatment (6, 108). However, BMD 
values may stabilize with time, as chronic ADT users (mean duration 33 months) showed 
no change in BMD over 12 months (72), whereas other reports show continuous declines 
in BMD over ten years, but used very small sample sizes (108). 
7.4 Fat Mass. The treatment of PCa is consistently associated with a significant 
increase in fat deposition (5, 20, 62, 125, 177, 184, 185). In studies with a variety of 
treatment lengths, there were significant percent increases in % fat (4.3 – 11%) which 
was greater with longer treatment (20, 62, 184-186). The absolute changes in % fat were 
typically between 2-3%. In a combined cross-sectional and longitudinal investigation, 
Levy et al. (125) reported only a trend for group differences increased fat mass, although 
there were group differences in % fat with healthy controls. A two year follow-up also 
revealed small but significant changes in % fat in both the acute and chronic PCa patients 
but there were no differences in the change between groups.  
The consistent increase in fat can lead to obesity, as well as diabetes, and 
metabolic syndrome. Treatment of PCa with ADT likely increases fat infiltration within 




assessed in PCa patients. Elevated levels of IMF are associated with insulin resistance 
and type 2 diabetes (71). In addition, fat infiltration is associated with reduced strength 
(70), poorer leg function (204), and greater incidence of mobility limitations in older 
adults (203). 
7.5 Fatigue. Fatigue may be the most prevalent and distressing side effect during 
and after cancer treatment and high numbers of patients report suffering from chronic 
fatigue during ADT (62, 103, 119, 176, 177). Forty percent of patients who remained on 
ADT reported chronic fatigue compared with only 25% in those who had ceased 
treatment (119). Aging and hormone therapy both likely contribute to fatigue by eliciting 
physiological events that promote loss in fatigue resistance and the ability or willingness 
to engage in physical activity. PCa patients have reduced physical activity levels after the 
onset of ADT (62) and similar declines in activity are also seen in animal studies (94, 95). 
The changes in body composition along with anemia are likely candidates affecting 
physical activity levels. These reduced levels, in part, result in overall reductions in 
fitness levels, leading to declines in physical function and ultimately to loss in QoL. 
7.6 Anemia. There is a connection between testosterone and hemoglobin levels, 
as prepubertal boys and girls have similar hemoglobin values that then increased in boys 
while remaining constant in girls after puberty (110). Moreover, testosterone 
administration in boys with constitutional delay of puberty led to increases in hemoglobin 
of 1.6 g/dL, bringing them to similar levels of that in normal adolescent boys (81). Thus, 
it is not surprising that the ablation of testosterone can lead to anemia (39, 192), which is 
linked to fatigue, QoL, and survival (139). Declines in hemoglobin of 6.5 – 10.5% are 




over three months of ADT are associated with shorter overall survival (10, 11). When 
anemia was examined as a dichotomous variable (hemoglobin greater vs. less than 12 
g/dL), black men were significantly more likely to be anemic than whites (11).  
7.7 Co-morbidities. PCa treatment is associated with a number of additional co-
morbidities, including insulin resistance (7, 186), cardiovascular disease (173, 199), and 
the metabolic syndrome (5, 21). Basaria et al. (7) observed a substantially higher 
prevalence of insulin resistance in PCa patients on ADT vs. PCa patients not on ADT and 
healthy aged-matched men, independent of age and obesity. Similar declines in insulin 
sensitivity were found after a 12-week prospective study at the onset of ADT (186). 
These findings are supported by two review articles that show a connection between 
ADT administration and insulin resistance (5, 107) and that this association becomes 
evident within the first few months of treatment. Cardiovascular morbidity is also 
elevated with ADT, as one group showed cardiovascular death rates of 5.5% for ADT 
patients and 2.0% in non-ADT patients (199) and another estimated that ADT increased 
cardiovascular mortality by 20% (173). Along these lines, several studies show elevated 
triglycerides and a trend for higher LDL cholesterol levels with androgen suppression 
(21, 185, 186). Finally, the use of ADT for 12 months revealed a higher prevalence of 
diabetes and metabolic syndrome (5), and 55% of the men in an ADT group met the 
criteria for metabolic syndrome compared with only 20% in the non-ADT and healthy 
control groups (21). 
The number of co-morbidities in PCa patients is affected by race, as black men 




(calculated using Medicare claims through diagnoses or procedures made from one year 
prior to one month following PCa diagnosis) (86). 
7.8 Physical Function. A decrease in physical function during ADT treatment is 
a common side effect (35, 65, 125) and is likely related to the loss of muscle mass and 
lower physical activity levels coupled with increases in fat mass and fatigue. Using cross-
sectional investigations, physical function assessed using common daily tasks and the 
short physical performance battery composite score were lower in chronic vs. acute ADT 
and non-ADT controls (Clay 2007, Levy 2008). Galvao et al. (65) consistently observed 
large differences between ADT patients and controls across a number of walking tasks, 
which exceeded the smallest meaningful clinical differences of 0.05 m/s (117, 133, 158). 
There was a study which found no differences between controls and men on ADT therapy 
(103), but it is not clear why this may have happened, considering that the functional 
tasks were identical to those used in studies reporting differences. One limitation of all 
these studies is that the PCa patients were high functioning, and in several cases those 
with severe impairments were either not recruited or dropped out. It is largely unknown if 
the effects of ADT are different in patients with limited function. An emphasis to recruit 
or retain these individuals should be considered for future studies. 
7.9 Quality of Life. QoL is perhaps the most egregious side effect of ADT and is 
intertwined with strength, body composition, fatigue, and physical function. Changes in 
the above traits that are well documented with ADT are likely to affect QoL. Thus, it is 
not surprising that men undergoing hormone therapy for PCa report reduced QoL (6, 40, 
103, 176). Several different QoL questionnaires are available, so direct comparisons are 




health perceptions sections but not the mental health sections were depressed in ADT 
patients compared to non-ADT patients (6, 40). Conflicting findings were reported by 
Joly et al (103), as these authors saw only trends for physical and functional differences 
compared to healthy controls when using a general QoL questionnaire but reported large 
differences when examining PCa-specific symptoms. Segal et al. (176) reported a small 
decline in QoL (3.3 units) over 12 weeks in men who had been on ADT, but this was not 
significant and was below the 6-10 unit clinically meaningful change for overall FACT-P 
score (31). 
In summary, ADT impacts on most of the body systems and the effects are most 
severe in the early stages of treatment. The long term consequences of ADT have been 
less studied, but the available evidence suggests that continuous declines in 
musculoskeletal health, physical function, and body composition can occur throughout 
treatment.  
8. Aging and ADT 
Many of the iatrogenic effects of ADT mimic the natural aging process but at an 
accelerated rate (25, 75, 91, 92). ST is considered the intervention of choice to offset the 
consequences of sarcopenia, aging, and chronic diseases (91, 92). In healthy older adults, 
ST can reverse the loss of muscle mass and strength (55, 90, 169), muscle power (42, 
160), bone (138, 171, 172), declines in resting metabolic rate (124), functional declines 
(63, 76, 79), and the reversal of increased regional fat deposition (198, 215), which can 
all lead to a deterioration in the QoL. It is, therefore, logical to postulate that the use of 
ST would be ideal in alleviating the adverse effects of ADT during the treatment of PCa. 




established that ST increases muscle mass and power in older adults (91, 92), it is unclear 
whether androgen ablation would blunt ST-induced muscle hypertrophy as limited 
investigations are available to support or reject such a hypothesis and none have 
examined this in black men on ADT (75).   
9. Exercise Training in PCa patients on ADT 
 Exercise training has only recently been used as a means of reducing the side 
effects of cancer treatment. Across many different cancer types, training is well tolerated 
by both patients undergoing treatment and in cancer survivors, conferring an array of 
physical and psychological benefits (59). However, the data were from primarily breast 
cancer patients using aerobic training, were plagued by small sample sizes, lacked 
randomization, and rarely examined ST. More recently, studies have addressed some of 
these limitations by including significant numbers of PCa patients and ST, and these 
individuals experienced gains in strength, endurance, and cardiopulmonary function but 
no effect on body composition (41). Very recently, the independent effects of ST in 
hormone dependent cancer treatment was reviewed (75) and, contrary to previous 
findings, changes in body composition in PCa patients were reported for the first time in 
two studies using high intensity ST. 
 Because the scope of this review of the literature is primarily focused on ST in 
PCa patients on ADT, only exercise interventions that meet these criteria will be 
included. In a few instances, the only data available regarding a particular side effect of 
ADT and the response to exercise is from animal studies. Information on additional types 
of cancer and various exercise interventions are outside the scope of this review but have 




 9.1 ST and ADT. To the best of our knowledge, the first investigation of ST in 
PCa patients on ADT was a  multi-site, RCT to examine the effects of 12 weeks of 
moderate intensity ST (60-70% of 1RM) on muscle endurance, fatigue and QoL (176). 
Compared to a waitlist control group (N = 73), men in the intervention group (N = 82) 
experienced significant gains in upper and lower body muscle endurance and had less 
interference from fatigue and enhanced QoL. There was no effect of ST on weight, BMI, 
waist circumference, or body composition, but the body composition analysis was limited 
to skinfolds. ST did not lead to increases in testosterone or PSA, which had been the 
reason why ST had not been previously recommended in ADT patients.  
In a follow up study, a two phase ST intervention lasting 20 weeks was used in 
ten men on ADT (61). Like previous studies (176), gains in muscle endurance were 
reported, along with increased upper and lower body strength, physical function, and 
balance with no change in testosterone or PSA (61). Neither FFM, fat mass, or BMD, 
assessed using DEXA, were altered with ST, although ultrasound imaging reported 
increased quadriceps muscle thickness but no changes at in the hamstrings, biceps, or 
triceps. The progressive ST protocol used higher intensities, ranging from 70-85% of 
1RM, based on the American College of Sports Medicine recommendations for ST in 
healthy adults (111), providing additional evidence that PCa patients on ADT respond 
well to ST. 
To investigate the importance of testosterone for increasing muscle mass and 
strength, healthy young men with limited ST experience were injected with an LHRHa or 
placebo for four weeks before completing an eight week ST program (115). The ADT 




resulted in a diminished response to ST, as gains in muscle strength were completely 
abolished and the gains in leg mass were attenuated compared with the placebo group, 
despite similar total training volumes. There were, however, no differences in the mRNA 
response between groups for the myogenic regulatory factors, myostatin, and IGF-1 
(116). Thus, testosterone does not appear to have any influence on these genes within the 
muscle hypertrophy pathway and the blunted increase in FFM appears to be the result of 
factors. 
One possible reason that increases in FFM are inconsistently observed in ADT 
patients could be influenced by the lack of direct measurements of muscle mass. Previous 
studies in PCa used either skinfolds (176) or DEXA (61, 115), each having several 
limitations. The most accurate methods of assessing muscle mass are CT and magnetic 
resonance imaging (MRI) (99). Cross-sectional area measurements at the mid-thigh and 
mid-arm derived from direct imaging techniques of skeletal muscle mass produced values 
that were nearly identical to actual measurements made in cadavers, and the correlations 
between CT, MRI, and cadaver were all 0.97 (145). Although CT and MRI imaging are 
accurate, non-invasive, and reliable, they are also expensive and time consuming as 
images must be manually outlined by a technician. There are also the inherent dangers 
due to radiation exposure with serial CT measurements (168). 
Direct measures of muscle mass in PCa patients was recently completed by 
Hansen and colleagues (74). In a small pilot study, ten PCa patients performed 12 weeks 
of eccentric resistance exercise using a recumbent leg cycle ergometer. The patients 
trained three times per week for 12 to 15 minutes per session at an intensity described as 




training in five men on ADT and five men who were not. The resistance exercise 
produced a significant gain of 2.9% in left leg MV of non-ADT patients. The right leg 
and neither leg in the ADT patients did not undergo any change in MV. Regrettably, the 
authors do not describe the methodology used to calculate MV in sufficient detail, nor do 
they specify whether boney landmarks were used to ensure adequate replication between 
baseline and post testing. 
There are two additional studies that investigated PCa patients and the response to 
training. Despite being well-controlled RCTs, neither study allows for the independent 
effects of ST on ADT to be examined. However, these studies do provide additional 
insight onto the training response in men with PCa. Segal et al (177) randomized 120 PCa 
patients receiving radiation therapy into ST, aerobic training, or usual care groups for 24 
weeks. Approximately 60% of the patients were on ADT, but the analyses did not adjust 
for this. Compared with usual care, ST participants had lower fatigue levels and 
improved QoL, aerobic fitness, upper and lower body strength, and triglyceride levels. ST 
also prevented an increase in % fat, which was observed in the usual care group. In a 
second RCT, 57 patients on ADT were assigned to a combined ST and aerobic program 
or usual care for 12 weeks (64). The authors report significant increases in FFM, similar 
in magnitude to that of Kvorning et al (115), but this is the first instance of muscle 
hypertrophy in PCa patients on ADT. Because aerobic training is not typically associated 
with gains in FFM, it is reasonable to assume that these gains were likely induced by the 
ST portion of the training program. In addition, the PCa patients increased their strength, 
physical function, and QoL with a decrease in fatigue. The changes in strength, muscle 




less than what the authors report in an earlier study (61) and could be the result of a 
shorter training program (12 vs. 20 weeks), the inclusion of aerobic training, or both. 
Combined ST and aerobic training has been shown to attenuate strength but not aerobic 
capacity gains in healthy individuals (12, 83).   
Over the past decade, a number of studies have been conducted evaluating the 
effectiveness of ST to reduce the negative side effects of ADT. One of the most striking 
and consistent observations that many research groups report are the high compliance and 
subsequent low dropout rates in this patient population. Only one investigation reported a 
high dropout rate as a study limitation (74). Moreover, the ST programs are well-
tolerated with few adverse events being reported. Although studies are only beginning to 
uncover the potential of complementary therapies, such as exercise training, to attenuate 
the side effects of PCa treatment, the existing data provide a strong basis for moving this 
area forward. 
9.2 Additional exercise training and ADT. To fully examine the widespread 
effects of ADT and exercise, there are measurements that cannot be completed using 
human subjects. For example, the effects of ADT on cardiac function and bone strength 
and composition (rather than just BMD) have been studied in rats. In addition, direct 
measures of muscle mass are very limited in PCa patients, but there are several relevant 
rodent studies that model ADT. While not the ideal model of ADT for humans, animal 
investigations provide additional insight and allow information to be obtained in 
situations where it might not be possible otherwise. 
Similar to humans, animal studies also present conflicting reports on hypertrophy. 




needle type electrical stimulation for two weeks with and without administration of the 
androgen receptor antagonist, oxendolone (96). The increase in muscle mass induced by 
electrical stimulation was effectively suppressed by the androgen receptor blockade as 
muscle hypertrophy was significantly lower than the control group. To the contrary, 
orchiectomized rats engaged in climbing a 200 cm tower to reach their drinking water 
had hindlimb muscle weights that were not significantly different compared to non-
climbing sham and orchiectomized rats (152). However, climbing exercise did reduced 
body fat mass in the castrated animals and preserved femur and vertebrae bone mass at 
four but not eight weeks. Access to voluntary wheel running in rats on ADT and control 
animals revealed no differences between groups for the cortical (compact) bone volumes, 
however, cancellous (spongy) bone volume was significantly reduced with ADT and 
running slightly improved it, although the volumes were still significantly lower than 
both control groups (94). These findings provide a better understanding of specific effects 
of ADT treatment on bone mass. The data are consistent with others (61), as exercise 
stimuli failed to induce changes in BMD. Bone loss with ADT remains an issue to be 
addressed in PCa patients (84). A phase III clinical trial has been proposed that will focus 
on, along with other ADT-related endpoints, bone health in PCa patients over 12 months, 
but the results have not yet been published (150). 
The other set of relevant studies in men on ADT are the home-based exercise and 
lifestyle modification programs (19, 36, 37). In a pilot study, 31 men on ADT completed 
a 12 week intervention composed of walking, stretching, and light resistance exercise 
(36). The patients also attended a group booster session at a cancer center every two 




reported, six minute walk distance and QoL were increased, and less fatigue was 
reported. Four months after the intervention concluded, there were trends for declining 
physical activity levels and QoL, indicating that importance of continued exercise during 
PCa treatment. In a more comprehensive study by the same research group, men 
randomized to the 16 week intervention failed to replicate their earlier findings as most of 
the primary outcomes did not undergo significant changes (37). This study had a high 
dropout rate, 34%, which included 11 patients from the intervention and 23 from the 
wait-list control group, and may have left the study underpowered to detect between and 
within group differences. Bourke et al (19) performed a randomized 12 week combined 
exercise intervention with a six month follow up. Men in the intervention group 
performed supervised ST and aerobic training sessions with additional walking sessions 
at home. Post testing revealed a decrease in fatigue and improved physical function, 
strength, and aerobic exercise tolerance in trained men compared to controls. There was 
no change in QoL with this intervention. Six months following the intervention, all of the 
above changes were maintained. The attendance for the supervised training sessions was 
95% and 87% for the home based portions. 
The home-based investigations highlight three particular issues with exercise 
intervention studies in PCa patients. First, when training sessions are scheduled at a 
university or cancer center, the exercise adherence rates are usually at or in excess of 
90% (19, 61, 64, 74, 177) whereas home based rates are lower (19, 37). Second, the 
intensity of home based exercises may be limited because the patients are training using 
Thera-Bands®, light weights, or body weight exercises (36, 37). The lower adherence rate 




However, studies of this nature are likely next steps for applying the findings of 
controlled laboratory investigations into more practical training interventions capable of 
reaching large numbers of patients. Finally, RCTs are considered the gold standard. 
However, subjects randomized to control groups are more likely to drop out (37, 176) or 
indicated they would not have participated in the study if they were allocated into the 
control group (61). Moreover, because exercise has been demonstrated to be beneficial, it 
calls into question whether it is ethical to assign individuals to a treatment that may 
inevitably receive a lower level of care. Studies have addressed this situation by assigning 
patients to a waiting control group (37, 64, 176). However, it is not clear if PCa patients 
in the control groups completed the training after the waiting period, what the exercise 
adherence rates were, or whether or not they experienced similar gains in the above cited 
studies. 
10. Potential Mechanisms of ST-Induced Hypertrophy during ADT 
 The final section of this literature review will examine the evidence for potential 
mechanisms to explain the gains in MV and FFM with ST in ADT patients. The number 
of studies on this topic is small, as only one study performed muscle biopsies (116) and 
no information on muscle proteins or cell signaling was presented in this study. Thus, 
most of the studies reviewed provided indirect evidence in healthy controls or blood 
biomarkers that are associated will protein synthesis and muscle mass gains. 
 10.1 Anabolic and Catabolic Hormone Responses to ST. The normal hormone 
response to acute resistance exercise and to ST in both young and older men and women 
have been well cataloged (112). Briefly, the typical profile shows a large surge in the 




increase in the androgens can activate transcription and translational events leading to 
increased protein synthesis and accretion of muscle mass. While ADT chronically 
suppresses testosterone, the acute and training hormonal responses with ST have not been 
extensively studied. There appear to only be two reports on this topic (60, 116). Galvao et 
al. (60) examined the acute and chronic hormone response to ST. Testosterone, as 
expected was highly suppressed and did not change in either instance. Growth hormone 
and IGF-1 showed small but not significant increases with an acute exercise bout and no 
changes with ST. Cortisol and C-reactive protein levels were unchanged in all instances 
while tumor necrosis factor alpha increased significantly with acute ST. Kvorning et al 
(116) observed that both free and total testosterone significantly decreased in the ADT 
group with a bout of resistance exercise, albeit the declines were rather small, and the 
placebo group underwent a large increase. Growth hormone increased significantly in 
both groups immediately after the training session and was no longer significantly 
elevated 15 minutes after cessation of exercise. No between group differences were 
noted. However, the growth hormone response with training was altered between groups, 
as men on LHRHa had a different response before training. The authors conclude that 
testosterone is of paramount importance for developing and maintaining muscle mass and 
strength with ST. This may conflict with data from Galvao et al (64) as the gains in FFM 
they report with combined training are similar to what is reported in the placebo group. 
Because Galvao and colleagues have only a non-exercise control (and no non-ADT + ST 
group), more definitive conclusions cannot be drawn without further study. 
 10.2 Cell Signaling and Protein Synthesis with ST. There is little doubt that 




elegantly demonstrated when 40 men were randomly allocated into one of four groups, 
no exercise, testosterone with no exercise, placebo plus exercise, and testosterone plus 
exercise for ten weeks.  Supraphysiological doses of testosterone (600 mg/week) were 
associated with gains in strength, FFM, and muscle cross-sectional area and these gains 
are compounded when undergoing ST (14). Furthermore, testosterone plays a role in 
protein synthesis, as the addition of exogenous testosterone increases fractional synthesis 
rates (FSR) (54, 200) and its suppression leads to declines (136).  
Presently, the signaling mechanisms that may be responsible for the accretion of 
muscle mass in men on ADT is unclear (15). Some (54, 200, 214), but not all (136) 
evidence suggests that testosterone may interact with IGF-1, via the PI3K-AKT-mTOR 
pathway, to activate p70S6K and protein synthesis (17, 69). However, the role of AKT as 
a signaling marker of increased protein synthesis in humans has recently been called into 
question as AKT phosphorylation has been observed with no changes in protein synthesis 
(134). Moreover, because a functional IGF-1 receptor is not necessary for muscle 
hypertrophy to occur (188), testosterone and its potential effects on IGF-1 may be 
beneficial rather than essential for increases in protein synthesis in response to 
mechanical overload. While there is ambiguity surrounding the exact signaling pathways 
associated with increased FSR, the literature strongly implicates a centralized role for 
mTOR (17, 69). For example, an increase in mTOR phosphorylation and FSR were 
observed following acute resistance exercise (47, 48) while rapamycin treatment to 
inhibit mTOR blocked the increase in FSR (49). Similarly, inhibition of the stretch 
activated channels during muscle contraction decreased activation of p70S6K (189). 




branched chain amino acids (BCAA) alone or combined with resistance exercise in both 
young and older adults led to increases in FSR and p70S6K phosphorylation, respectively 
(77, 105, 205). Persistent daily supplementation of BCAA over three months also 
increased FSR and FFM in older women (45). 
Testosterone may also inhibit the catabolic effects of the GR (106) and atrogin-1 
gene expression (219). Recent data indicates that there may be crosstalk between mTOR 
and the GR. In rat gastrocnemius and soleus muscle, dexamethasone treatment was used 
to activate the GR and increased transcription of REDD1, atrogin-1, MuRF1, FoxO1, 
FoxO3, myostatin, and KLF15, and inhibition of mTOR activity was observed (182). The 
effects were more prominent in the fast-twitch gastrocnemius fibers. Activation of mTOR 
with amino acid supplementation blocked GR induction of its target genes which were 
rescued when mTOR was inhibited by rapamycin (182). Thus, the loss of the testosterone 
with ADT and the declines in FFM could be explained by a shift in the dynamic balance 
between protein synthesis and breakdown. In this regard, ST may be able to reduce the 
deleterious effects of ADT on muscle through activation of mTOR and thereby increasing 
protein synthesis (48). The inhibition of mTOR completed ablated the increase in FSR 
with acute resistance exercise (49), implicating this as a plausible pathway to explain 
increases in FFM with ST in individuals with very low testosterone, e.g., in women or in 
men on ADT. 
11. Summary 
There appears to be a racial disparity regarding the prevalence and mortality rates 
of PCa. The exact cause of these differences remains elusive. Some studies implicate 




access to health care suggest otherwise. Race may also affect the prescribed treatment 
options, as black men are less likely to receive aggressive treatment, including ADT.  
ADT has been associated with a number of adverse effects, notably the loss of 
musculoskeletal health and physical function along with altered body composition (Table 
9). Minimizing the side effects of PCa treatment is crucial in order to enhance QoL, as 
simply living longer is not an acceptable outcome. 
One of the most effective complementary therapies to offset ADT treatment is ST. 
Most exercise intervention studies are well tolerated by the patients and have 
demonstrated significant improvements in muscle strength and function, physical 
function, and QoL, and a few also reported of increases in FFM. Many of the 
improvements are on par with changes observed in healthy older adults with ST. Future 
investigations should focus on the ability of ST to reverse ADT-induced muscle atrophy 
and the potential mechanisms by which the increase in muscle mass is occurring. 
Additional areas of study could also in include interventions to reversed ADT-induced 
BMD loss and the high incidences of insulin resistance and metabolic syndrome in PCa 
patients. This additional information will help guide clinicians in exercise prescription 
designed specifically to reduce comorbidities and particular side effects to enhance QoL 
















on ADT Refs 
Research 
hypothesis 




▼▼ (6, 65, 
177, 211) 








▼▼ (20, 62, 
65, 184-
186, 201) 
↔, ?? (61, 74) ↑ 
Power ▼ (122, 
141, 
161) 
??  ??  ↑ 
Endurance ▼,▲ (89, 
161, 
164) 
↔ (65, 176, 
177) 
↑ (61, 176) ↑ 
Fat ▲ (13, 88, 
118) 
▲▲ (6, 20, 33, 
40, 62, 65, 
177, 184-
186, 201) 
↔ (61, 176, 
177) 
↔ 
IMF ▲ (143, 
220) 
??  ??  ↔ 
SCF ▼ (88, 
143) 
??  ??  ↔ 




↔ (61) ↔ 
Fatigue ▲ (147) ▲▲ (62, 82, 
103, 119, 
177, 190) 
↓ (176, 177) ↓ 
ADL ▼ (122, 
147) 
▼▼ (35, 62, 
65, 103, 
125) 
↑ (61, 74) ↑ 
QoL ▼ (149, 
209) 
▼▼ (6, 40, 82, 
103, 151, 
190) 
↑ (74, 176, 
177) 
↑ 
¶ Effect of ADT compared with the Effect of Aging 
ADT = Androgen Deprivation Therapy; IMF = Intermuscular Fat; SCF =  
Subcutaneous Fat; BMD = Bone Mineral Density; ADL = Activities of Daily Living 
simulations; QoL = Quality of Life 
▲, Increase with age/ADT; ▼, Decrease with age/ADT; ↑, Increase with ST, ↓, 
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